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1. INTRODUCTION 
 Pharmaceutical analysis plays a vital role in the Quality Assurance and Quality control of 
bulk drugs. Analytical chemistry involves separation, identification, and determining the relative 
amounts of components in a sample matrix. Pharmaceutical analysis is a specialized branch of 
analytical chemistry that derives its principles from various branches of sciences like physics, 
microbiology, nuclear science, and electronics etc. Qualitative analysis is required before a 
quantitative analysis can be undertaken.  
  
 Analytical chemistryis defined asthescience and art of developing sensitive, reliable and 
accurate method for determining the composition of materials in terms of elements or compounds 
which they contain. Pharmaceutical analysis comprises those procedures necessary to determine the 
identity, strength, quality and purity of drug and chemicals Pharmaceutical analysis deals mainly 
with bulk materials, dosage forms and more recently, biological samples in support of bio-
pharmaceutical and pharmacokinetic studies.[1] 
  
 Pharmaceutical analysts in research and development (R&D) of  pharmaceutical industry 
plays a very comprehensive role in new drug development and  follow up  activities toassure that a 
new drug product meets the established standards, its stability and continued to meet the purported 
quality throughout its shelf life. 
  
 The different activity of R&D includes drug development, (synthesis and manufacture), 
formulation, clinical trials, evaluations and finally launching i.e. finished products. 
Closelyassociated with these are regulatory and quality assurance functions. 
  
 Analytical method development and validation is a good research in the field of 
Pharmaceutical analysis, utilized to determine the drug content in bulk and pharmaceutical dosage 
forms and in biological fluids like blood, serum, urine etc. In view of the industrial scenario and 
literature, it was noted that chromatographic techniques like HPLC, LC–MS/MS methods have 
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created revolutionary precision and accuracy in quantification of drugs in Formulation and in 
biological fluids even at low concentration.[2] 
Need for pharmaceutical Analysis[3] 
 New drug development. 
 Method Validation as for ICH Guidelines 
 Research in Pharmaceutical Sciences 
 Clinical Pharmacokinetic Studies 
 
 When promising results are obtained from explorative validation performed during the 
method development phase, then only full validation should be stared. The process of validating a 
method cannot be separated from the actual development of method conditions. 
 A diversity of analytical techniques such as spectroscopy (UV-Visible), gas 
chromatography (GC), high performance liquid chromatography (HPLC), Ultra performance liquid 
chromatography (UPLC) supercritical fluid chromatography (SFC), capillary electrophoresis (CE) 
coupled with selective detectors (diode-array detector (DAD) and mass spectrometry (MS) are 
normally used to accomplish the above requirements. 
 In spite of various techniques existing, HPLC and UPLC has become a universal tool for 
pharmaceutical and biomedical research, as well as product analysis. The accessibility of fully 
automated systems, excellent quantitative precision, accuracy, sensitivity, selectivity and increased 
selection of column stationary phases, applicability to a lane variety of sample, Matrices and ability 
to hyphenate with several spectroscopic detectors has made HPLC or UPLC the instrument of 
choice for the analysis of most categories of drugs. 
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 Correspondingly, HPLC or UPLC methods are profusely used in the field of biomedical 
analysis, viz. therapeutic drug monitoring, pharmacokinetic and bioequivalence studies. The assay 
of drugs in blood, plasma and tissues presents analytical challenges. The drug substance is typically 
present at low concentrations, bound to proteinaceous material and endogenous compounds 
typically present in the samples can interfere with the analysis. For these reasons, the analytical 
methods usually be highly sensitive to detect analytes at low concentrations and required a sample 
pre-treatment procedure such as liquid-liquid extraction (LLE) or solid phase extraction (SPE), to 
isolate the analyte from the complex biological matrix. Hence, high sensitivity and automation of 
sample processing tools to deal with large number of samples are strong incentives for the 
consideration of HPLC or UPLC methods in biomedical analysis. 
UPLC comes from HPLC .Ultra Performance Liquid Chromatography (UPLC) is a 
relatively new technique giving new possibilities in liquid chromatography, especially concerning 
decrease of time and solvent consumption. This enhanced the demand for UPLC methods for the 
simultaneous determination of drugs in pharmaceutical mixtures.[4] 
 
1.1 TYPES 
 Traditionally, analytical chemistry has been split in to two main types, qualitative and    
quantitative: 
 
1.1.1 Qualitative 
• Qualitative inorganic analysis seeks to establish the presence of a given element or inorganic 
compound in sample. 
• Qualitative organic analysisseeks to establish the presence of a givenfunctional group or 
Organic compound in a sample. 
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1.1.2Quantitative 
• Quantitative  analysis  seeks to  establish   the  amount  of  given  element  or  compound  in  a 
sample. 
 Most modern analytical chemistry is categorized by two different approaches such 
asAnalyticaltargets or analytical methods[5]. 
 
 By Analytical Targets 
• Bio analytical chemistry 
• Material  analysis 
• Chemical analysis 
• Environmental analysis 
• Forensics 
 
 By Analytical Methods 
• Spectroscopy 
• Mass spectroscopy 
• Spectrophotometry and colorimetric 
• Chromatography and Electrophoresis 
• Crystallography 
• Microscopy 
• Electrochemistry 
 Traditional analytical techniques 
• Titration 
• Gravimetry 
• Inorganic qualitative analysis 
 
 
 Instrumental analysis 
• Spectroscopy 
• Mass spectroscopy 
• Crystallography 
• Electrochemical Analysis 
• Thermal analysis 
• Separation 
• Hybrid Techniques 
• Microscopy  
Analytical chemistry research is largely driven by performance  (sensitivity,  selectivity, robustness,  
linear range , accuracy,  precision,  and speed),  and  cost ( purchase, operation, training, time,  and  
space). 
 Analytical chemistry  has played critical roles In  the  understanding of    basic science to  a 
variety   of  practical applications, such as biomedical  applications, environmental  monitoring,  
quality control   of  industrial  manufacturing,  forensic science and so on. 
 Pharmaceutical   analysis plays a very significant  role  in  quality  control  of  
pharmaceuticals  through  a rigid  check on raw  materials used in manufacturing of formulations   
and on  finished products. It also plays an important role building up   the   quality productsthrough 
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in processquality control.  Pharmaceutical   analysis is the application of principles   of    analytical 
chemistry to drug analysis. 
 The  analytical chemistry may be defined as the   science  of  developing  sensitive,  relative 
and accurate methods   for  determining the composition of materials  in terms of  elements  or  
compounds  which  they contain.The most importantcomponent aspectanalysis is quantitative 
chemical analysis. In the presence age, the physical, chemical andbiological analysis, involve 
computerized techniques to facilitate better result.[6] 
 
1.2. ANALYTICAL TECHNIQUES[7] 
SPECTROSCOPY APPLICATIONS 
Atomic  Absorption and Emission 
spectroscopy(AAS/AES) 
To analyse alkali and alkaline earth metals indilute solution, 
natural liquids, and extracts at trace levels. 
Ultraviolet-visibleSpectroscopy 
(UV/Vis) 
To analyse molecular (organic) and ionic species capable 
ofabsorbingat UV orVisible wave lengths in dilute solutions. 
Fourier Transform 
infraredSpectroscopy(FT-IR) 
To analyse only molecular compounds(Organiccompounds, 
natural products, polymers, etc.). 
Fourier  Transform  
RamanSpectroscopy (FT-Raman) 
To analyse molecular (organic) compounds which are not 
responding well in the IR region and hence, it is an alternative 
IR. 
Nuclear Magnetic 
ResonanceSpectroscopy 
To identify and characterize the organic and inorganic 
compounds. 
Microwave spectroscopy To analyse simple gaseous molecules in far in region to study 
their stereo chemistry. 
Electron spin resonance 
Spectroscopy (ESR) 
To study the information and lifetime of the free radicals 
formed in organic reactions and all finds applications in 
biological works. 
Molecular 
Fluorescencespectroscopy 
To study the molecular and ionic compounds in dilute 
solutions capable giving fluorescence, applications in vitamin 
analysis. 
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1.2.1 CHROMATOGRAPHY 
1.2.2 THERMAL ANALYSIS 
1.2.3 X-RAY TECHNIQUE 
X-ray fluorescence(XRF) 
Spectrometry 
To identify the elements and their states present in the surface 
of the materials. 
X-ray Diffractometry(XRD) To study the crystalline properties of solid substances. 
1.2.4 MICROSCOPY 
Scanning electron 
microscopy(SEM) 
To Study the topography, electronic structure and 
compositions of metals, ceramics, polymers, composites and 
biological materials. 
Transmission electron 
microscopy(TEM) 
To study the local structures, morphology, and Dispersion of 
multi-component polymers, cross sections of crystallizations 
of metallic alloys, semiconductors, microstructure of 
composites, etc. 
Scanning probe microscopy(SPM) To study the hardness and topography of materials like 
ceramics, polymers, composites, etc. on a nano scale range. 
High Performance Liquid  
chromatography 
To separate and analyse complex mixtures or solutions which 
include liquids and solids and solids of both organic and 
inorganic origins.   
Gas chromatography To separate and analyse mixtures of volatile organic 
compounds, solvent extracts and gases. 
Thermo gravimetric analysis 
(TGA) 
To study the mass charges of materials like polymers, glasses, 
ceramics, etc.,    such as evaporation ,decomposition gas 
absorption, desorption, dehydration  etc., 
Thermo mechanical analysis 
(TMA) 
To study the expansion coefficient of composite and laminate 
materials. 
Differential  thermal analysis 
(DTA) 
To  study the exothermic and endothermic behaviour of clay 
materials, ceramics, ores, etc., 
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1.2.5 ELECTRO-CHEMICAL TECHNIQUES  
Polarography 
To study and determine metals, metal complexes, and organic 
compounds in trace levels. 
Capillary electrophoresis(CE) To study and characterize biologically active compounds like 
proteins, amino acids and bio- molecules.  
1.2.6 MISCELLANEOUS TECHNIQUES 
Total  organic carbon analyser 
(TOC) 
To monitor pollutants in environmental studies by 
determining the carbon contents of the trace compounds. 
Elemental Analyser(CHN/S) 
To estimate percentage compositions of elements like carbon, 
hydrogen, nitrogen, and sulphur present in  newly synthesized 
organic compounds, pharmaceuticals,  etc. 
Polarimetry 
To analyse and quantitative optically active compounds   like   
sugar. 
Circular Dichroism(CD) and 
optical  Rotatory Dispersion(ORD) 
To get the structural information of optically active 
compounds like, amino acids, proteins etc. 
Vibrational Circular  
Dichroism(VCD) 
and Vibrational Linear 
Dichroism(VLD) 
Same as above but in the IR region. VLD measurement is   
employed    to    study     the    molecular   orientations   of   
thin polymer films. 
Mass spectrometry(MS) 
To identify the organic compounds.  Often   used    as 
detectors   with   HPLC and GC.  
Laser Light scattering 
system(LLIS) 
In the study ofmacromolecules like polymers,   Gels, proteins, 
etc. for determining molecular mass and size and their 
associations.  
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1.3 CHROMATOGRAPHY 
1.3.1 Introduction to Chromatography 
 Chromatography is relatively a new technique which was first invented by   M. Tswett, a 
botanist in 1906 in Warsaw. In that year, he was successful in doing the separation of chlorophyll, 
Xanthophyll and several other coloured substances by percolating vegetable extracts through a 
column of calcium carbonate. The calcium carbonate column acted as an adsorbent and the different 
substances got adsorbed to different extent and this gives rise to coloured bands at different 
positions, ion the column. Tswett termed this system of coloured bands as the chromatogram and 
the method as chromatography after the Greek words Chroma and graphs meaning “colour” and 
“writing” respectively. However, in the majority of chromatographic procedures no coloured 
products are formed and the term is a misnomer. 
 Chromatography is a non-destructive procedure[8] for resolving a multi-component mixture 
of trace, minor, or major constituents into its individual fractions. Different variations may be 
applied to solids, liquids, and gases. While chromatography may be applied both quantitatively, it is 
primarily a separation tools. 
 
1.3.2 Definition of Chromatograph 
 Chromatography may be defined as a method of separating a mixture of components into 
individualcomponents through equilibrium distribution between two phases. Essentially, the 
technique of chromatography is based on the differences in the rate at which the components of a 
mixture move through a porous medium (called stationary phase) under the influence of some 
solvent or gas (called moving phase)[8]. 
The chromatography method of separation [8], in general, involves the following steps: 
1. Adsorption or retention of a substance or separation, in general involves the following steps: 
2. Separation of the adsorbed substances by the mobile phase. 
3. Recovery of the separated substances by a continuous flow of the mobile phase, the method 
being called elution. 
4. Qualitative and quantities analysis of the eluted substances. 
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1.3.3 Classification of Chromatographic Techniques
 According to nature 
and mobile phase: 
 Gas  Solid chromatography
 Gas  liquid chromatography
 Solid liquid chromatography
 Liquid liquid chromatography
 
 
1.3.3.1 Adsorption Chromatography:
 Adsorption chromatography
around. It utilizes a   mobile   liquid or   gaseous   phase   that is   
a stationary solid phase. The equilibration    between the   mobile   and   stationary phase
the separation of different solutes.
Figure 1.1 A
1.3.3.2 Partition Chromatography:
 This form of chromatography is based on a thin film formed on the surface of a solid
by a liquid stationary phase. Solute equilibrates between the mobile phase and the
 
of stationary 
 
 
 
 
 According to mechanisms of 
separation: 
 Adsorption chromatography
 Partition chromatography
 Ion exchange chromatography
 Molecular exclusion 
chromatography
 Affinity chromatography
 Chiral chromatography
 
[8]is probably one of the oldest types of   chromatography   
adsorbed   onto   the    surface   of   
 
dsorption phenomenon in chromatography
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support 
stationary liquid. 
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Figure 1.2
 
1.3.3.3 Ion Exchange Chromatography:
 In this type of chromatography, the use of a resin (the stationary solid phase) is used to
covalently attach anions or captions onto it. Solute ions of the opposite charge in the
phase are attracted to the resin by electrostatic forces.
Figure 1.3Ion exchange phenomenon in chromatography
1.3.3.4 Molecular Exclusion Chromatography:
 Also known as   gel   permeation or   gel filtration
Attractive interaction between the 
through a porous gel which separates the molecules 
 
Partition phenomenon in chromatography
 
 
 
 
[8]
, this type of chromatography lacks 
stationary phase and solute. The liquid or 
according to its size. 
C 
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mobile liquid 
 
 
an 
gaseous Phase passes     
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Figure 1.4Molecular Exchange phenomenon in chromatography
 The pores are normally small and exclude the larger solute molecules, but allow smaller
molecules to enter the gel, causing them to flow through a larger volume. This causes the
molecules to pass through the column at a faster rate than the smaller ones.
 
1.3.3.5 Affinity Chromatography:
 Affinity chromatography
phases.  This technique is   mostly   used   the   field of biotechnology, micro biology, biochemistry 
etc. 
 
1.3.3.6 Chiral Phase Chromato
 Separations of opticalisomer can
operate   for different types of stationary
used for this type ofchromatography aremostly chemically 
separation, HPLC and HPTLC methods 
because of itssimplicity, precision
 
1.3.3.7 High Performance Liquid 
 The acronym HPLC, coined by the late Prf. 
originally indicated the fact that high pressure was used to genera
chromatography in packed columns
 
 
 
 
 
[8]
   uses the affinity of the sample with   specific   stationary   
graphy: 
 be done by using stationary phases 
 phasesand different samples.The stationary phases
bonded silica gel
have widely been exploited in 
, accuracy, andreproducibility of results. 
Chromatography 
Casaba Horvath for his 1970 
te the flow required for liquid 
[9]
.  
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 In the beginning, pumps only had a pressure capability of 500 psi. This was called high 
pressure liquid chromatography, or HPLC
The early 1970s saw a tremendous leap in technology. These new HPLC instruments could 
develop up to 6,000 psi of pressure, and incorpo
HPLC really began to take hold in the mid
 With continued advances in performance during this time (smaller particles, even higher 
pressure), the acronym HPLC remained the same, but the na
liquid chromatography. 
 High performance liquid chromatography
analytical chemistry. It has the ability to separate, identify, and quantitative the compounds that are 
present in any sample that can be dissolved in a liquid
 
Figure 1.5High-Performance Liquid Chromatography [
  
Today, compounds in trace concentrations as low as parts per trillion may easily be 
identified. HPLC can be, and has been, applied to just about any s
food, neutraceuticals, cosmetics, 
The components of a basic high
shown in the simple diagram in Figure
 
. 
rated improved injectors, detectors, and columns. 
-to late-1970s[9]. 
me was changed to high performance 
[9]
 is now one of the most powerful tools in 
. 
HPLC] System
ample, such as pharmaceuticals, 
environmental matrices, forensic samples and industrial chemicals.
-performance liquid chromatography (HPLC)
 1.5. 
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 A reservoir (Solvent Delivery) holds the solvent (called the mobile phase, because it 
moves). A high-pressure pump solvent manager is used to generate and meter a specified flow rate 
of mobile phase, typically millilitres per minute. 
An injector (sample manager or auto sampler) is able to introduce (inject) the sample into 
the continuously flowing mobile phase stream that carries the sample into the HPLC column. 
The column contains the chromatographic packing material needed to effect the separation. 
This packing material is called the stationary phase because it is held in place by the column 
hardware. A detector is needed to see the separated compound bands as they elute from the HPLC 
column (most compounds have no colour, so we cannot see them with our eyes). 
The mobile phase exits the detector and can be sent to waste, or collected, as desired. When 
the mobile phase contains a separated compound band, HPLC provides the ability to collect this 
fraction of the elute containing that purified compound for further study. This is called preparative 
chromatography. The high-pressure tubing and fittings are used to interconnect the pump, injector, 
column, and detector components to form the conduit for the mobile phase, sample, and separated 
compound bands. 
The detector is wired to the computer data station, the HPLC system component that records 
the electrical signal needed to generate the chromatogram on its display and to identify and 
quantitative the concentration of the sample constituents. Since sample compound characteristics 
can be very different, several types of detectors have been developed. For example, if a compound 
can absorb ultraviolet light, a UV-absorbance detector is used. If the compound fluoresces, a 
fluorescence detector is used. If the compound does not have either of these characteristics, a more 
universal type of detector is used, such as an evaporative-light-scattering detector (ELSD). The 
most powerful approach is the use multiple detectors in series.  
For example, a UV and/or ELSD detector may be used in combination with a mass 
spectrometer (MS) to analyse the results of the chromatographic separation. This provides, from a 
single injection, more comprehensive information about an analyte. The practice of coupling a mass 
spectrometer to an HPLC system is called LC/MS. 
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1.3.3.8 Ultra Performance Liquid C
 In 2004, further advances in instrumentation and column technology were made to achieve 
very significant increases in resolution
with smaller particles (1.7 micron) and instrumentation with specialized 
deliver mobile phase at 15,000 psi (1,000 bars) were needed to achieve a 
A new system had to be holistically created to perform ultra
chromatography[10], now known as UPLC technology
Basic research is being conducted today by scientists worki
smaller than 1-micron-diameter particles and instrumentation capable of performing at100,000 psi. 
This provides a glimpse of what we may expect in the future. U
Performance Liquid Chromatography
speed and sensitivity analysis. It uses fine particles and saves time and reduces solvent 
consumption. UPLC is comes from HPLC. HPLC has been the evolution of the packing materials 
used to effect the separation.  
Figure 1.6Ultra-
  
 
hromatography 
, speed, and sensitivity in liquid chromatography. Columns 
new levelof
.  
ng with columns containing even 
[10]
. It improves in three areas: chroma
Performance Liquid Chromatography [UPLC] Instrument
C 
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 performance. 
-performance liquid 
 
PLC refers to Ultra 
tographic resolution, 
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An underlying principle of HPLC dictates that as column packing particle size decreases, 
efficiency and thus resolution also increases. As particle size decreases to less than 2.5µm, there is a 
significant gain in efficiency and it’s doesn’t diminish at increased linear velocities or flow rates 
according to the common Van Demeter equation. By using smaller particles, speed and peak 
capacity (number of peaks resolved per unit time) can be extended to new limits which is known as 
Ultra Performance. 
The classic separation method of HPLC (High Performance Liquid Chromatography)[10] has 
many advantages like robustness, ease of use, good selectivity and adjustable sensitivity. The main 
limitation is lack of efficiency compared to gas chromatography or the capillary electrophoresis due 
to low diffusion coefficients in liquid phase, involving slow diffusion of analytes in the stationary 
phase. The Van Demeter equation shows that efficiency increases with the use of smaller size 
particles but this leads to a rapid increase in back pressure, since most of the HPLC system can 
operate only up to 400 bar. That is why short columns filled with particles of about 2µm are used 
with these systems, to accelerate the analysis without loss of efficiency. 
 To improve the efficiency of HPLC separations, the following can be done, 
(1) Work at higher temperatures 
(2) Use of monolithic columns  
 
1.3.3.8.1Principle 
 The UPLC is based on the principal of use of stationary phase consisting of particles less 
than2 μm (while HPLC columns are typically filled with particles of 3 to 5 μm). The underlying 
principles of this evolution are governed by the van Demeter equation, which is an empirical 
formula that describes the relationship between linear velocity (flow rate) and plate height (HETP 
or column efficiency).  
 The Van Demeter curve, governed by an equation with three components shows that the 
usable flow range for a good efficiency with small diameter particles is much greater than for larger 
diameters. 
H=A+B/v+Cv 
Where; 
A, Band Care constants 
Vis the linear velocity, the carrier gas flow rate. 
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 The A term is independent of velocity and represents "eddy" mixing. It is smallest when the 
packed column particles are small and uniform. 
 The B term represents axial diffusion or the natural diffusion tendency of molecules. This 
effect is diminished at high flow rates and so this term is divided by v. 
 The C term is due to kinetic resistance to equilibrium in the separation process. The kinetic 
resistance is the time lag involved in moving from the gas phase to the packing stationary 
phase and back again. The greater the flow of gas, the more a molecule on the packing tends 
to lag behind molecules in the mobile phase. Thus this term is proportional to v. 
 
Therefore it is possible to increase throughput, and thus the speed of analysis without affecting 
the chromatographic performance. The advent of UPLC has demanded the development of a new 
instrumental system for liquid chromatography, which can take advantage of the separation 
performance (by reducing dead volumes) and consistentwith the pressures (about 8000 to 15,000 
PSI, compared with 2500 to 5000 PSI in HPLC). Efficiency is proportional to column length and 
inversely proportional to the particle size. Therefore, the column can be shortened by the same 
factor as the particle size without loss of resolution. The application of UPLC resulted in the 
detection of additional drug metabolites, superior separation and improved spectral quality. 
 
 Advantages 
• Drastically decreases the run time compared to HPLC.  
• Provides selectivity, sensitivity and dynamic range of LC analysis. 
• The time spent on optimizing new methods can also be greatly reduced.  
• Expands the scope of Multi residue method 
• UPLC’s fast resolving power quickly quantifies related and unrelated compounds.  
• Use of very fine particle size of novel separation materials reduces the analysis time.  
• Operation cost is reduced and less solvent consumption.  
• Increases sample throughput and enables manufacturers to produce more material that 
consistently meet or exceeds the product specifications, potentially eliminating 
variability, failed batches, or the need to re-work material. 
• The time needed for column equilibration while using gradient elution and during 
method validation is much shorter. 
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 Disadvantages 
• One of the major disadvantages in UPLC is the higher back pressures compared to 
conventional HPLC which in turn may reduce the life of the columns. 
• This backpressure can be
• In addition, the phases of less than 2
limited use. 
 
Table 1.1Comparison between and HPLC and UPLC
Characteristics 
Particle size 
Maximum back pressure 
Analytical column 
Column dimensions 
Column temperature 
Injection volume 
 
1.3.4Parameters in chromatography
 Retention time(Rt) 
 
• Retention time[11] is the time of elution 
 
 
 
 reduced by increasing the column temperature. 
μm are generally non regenerable
 
HPLC 
3 to 5m Less than 2m
35-40MPa 103.Mp
Altima C18 Acuity UPLC BEH C
150X3.2mm 150X2.1mm
300C 650c 
5µL(std.In100% Me OH) 2µL(std.In100% ME OH)
 
 
of peak maximum after injection of compound.
C 
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 and thus have 
UPLC 
 
a 
18 
 
(7)
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 Retention volume (Vr) 
 Retention   volume[11] is   the volume of mobile phase to elute 50% of the compound from 
the column. It is the product of retention time and flow rate. 
Component   Retention volume (Vr) could split into two parts: 
 Reduced retention volume is the volume of the eluent that passed through the  column 
while the component 
 Dead volume is the volume of the eluent that passed the column while the component was 
moving with the liquid phase. 
 
 Separation factor(S): 
 Separation   factor[11]   is    the ratio of partition   coefficient   of   the two   components   to 
be separated. 
It can be expressed   and determined by using the following equation:  
S=Kb/Ka=tb-t0/ta-t0 
Wheret0 = retention time of unretained   substance. 
Kb  = partition coefficients of b and a  
tb,ta  = retention time of substance of band a 
S  = depends   in   liquid   phase,   column    temperature  
  
If there is more difference in partition coefficient between two compounds,   the peaks are far 
apart and the separation factors are more.  If the   separation   coefficients   of   two    compounds 
are similar, then the peaks are closer and the separation factor is less. 
 
 Capacity factor (k') 
 It is the measure of how well the   sample   molecule is    retained   by   the   column   during 
an isocratic separation.  It is affected by solvent     composition,   separation and aging and 
temperature   of separation[11].  
K' = V1-V0/V0 
Where   V1 =   retention volume at apex of the peak. 
             V0 =   void volume of system where an unretained component elutes. 
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 Selectivity (α) 
• The selectivity is a measure of relative retention of two components in a mixture. 
• Selectivity[11] is the ratio of the capacity factors of both corresponding peaks. 
• It can be calculated by following formula: 
 
 
 
 Resolution (r): 
 Resolution expresses the separation of two components in a mixture that determined by the 
following equation: 
 
Where,  
 t2and t1 are the retention times of the two components. 
 w2andw1 are the corresponding widths at the bases of the peaks obtained by 
 Extrapolating the relatively straight sides of the peaks to the baseline. 
 Where electronic integrators are used, it may be convenient to determinethe resolution, R, 
by the following equation: 
 
Where by W1 h/2 andW2 h/2 are the widths at half-height of corresponding peaks.  
For better separation, the ideal value of R is 1.5 
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 Theoretical plates (N)
 The number of theoretical plates
following equation: 
Where, 
 T is retention time of the peak 
 W is the 
 Wh/2 is width at half
 
• Value of theoretical plates, higher than 4000 is indicating good column performance
 
 Height Equivalent to a Theoretical Plate
 A theoretical plate[11] is an ima
solute between stationary phase and mobile phase 
a functional unit of the column. 
A theoretical plate can be 
HETP is less, the column is more 
HETP =length of the column /no. of theore
HETP is given by Van Demeter
Where  
 
 
: 
[11]
 is a measure of column efficiency. It is
 
 
width of the peak.  
-height of the peak.  
(HETP): 
ginary or hypothetical unit of a column where distribution of 
has attained   equilibrium. 
 
of any height, which describes the efficiency of 
efficient. If HETP is more, the column is less efficient.
tical plates  
 equation. 
HETP = A+B/u+Cu 
C 
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 expressed by 
. 
It can also be called as 
separation. If 
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A=Eddy diffusion term or multiple path diffusion which arises 
This can be minimized by uniformity 
 
 B = longitudinal diffusion term or molecular diffusion.
           C = Effect of mass transfer.
           U = flow rate 
 
 Asymmetry factor: 
  
The asymmetry factor is a measure of peak
of the peak to the back slope divided by the distance from
slope, with all measurements made at 10% of the maximum peak height.
• Fronting: 
 Fronting[11] is due to the saturation of   stationary    phase   and can be avoided by   using   
less quantity of   sample. 
 
due to the packing of the
of packing. 
 
 
or velocity of mobile phase. 
 
 tailing. It is defined as the distance from the center line 
 the center line of the peak to the
 
 
C 
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• Tailing: 
 It is  due  to  the more active adsorption  sites can be eliminated by  support  pretreatment,  
more polar  mobile phased  increasing  the amount of liquid phase.  
 
1.3.5 Method Development and Optimization of Chromatographic Conditions 
 Methods for analysing drugs in multi component dosage forms can be developed if the 
nature of the sample, namely, its molecular weight, polarity, ionic character and the solubility 
parameter are in hand. Until and unless considerable trial and error procedures have not performed, 
an exact recipe for HPLC cannot be provided[12]. 
 The most difficult problem usually is where to start, what type of column is worth trying 
with what kind of mobile phase. In general one begins with reversed phase chromatography, when 
the compounds are hydrophilic in nature with many polar groups and are water soluble. 
 
1.3.5.1Selection of stationary phase/ column: 
 Selection of the column is the initial and the most noteworthy step in method development.  
 
The proper choice of separation column includes three different approaches. 
1. Selection of separation system  
2. The particle size and the nature of the column packing 
3. The physical parameters of the column i.e. the length and the diameter.  
 Some of the crucial parameters considered while selecting chromatographic Columns. They 
are length and diameter of the column, packing material, Shape of the particle, Size of the particles, 
% of Carbon loading, Pore volume, Surface area and End capping. The column is selected 
depending on the nature of the solute and the information about the analyte, Reversed phase mode 
of chromatography facilitates information about the analyte.  
 Reversed phase mode of chromatography[12] facilitates a wide range of columns like dim 
ethylsilane (C2), butylsilane (C4), octylsilane (C8), octadecylsilane (C18), base deactivated silane 
(C18) BDS, cyanopropyl (CN), nitro, amino etc. 
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1.3.5.2Selection of mobile phase: 
 The primary objective in selection and optimization of mobile phase[12] is to achieve 
optimum separation of all the individual impurities and degrades from one other and from analyte 
peak. In liquid chromatography, the solute retention is governed by the solute distribution factor, 
which reflects the different interactions of the solute-stationary phase, solute-mobile phase and the 
mobile phase-stationary phase. 
For a given stationary phase, the retention of the given solute depends directly upon the 
mobile phase, the nature and the composition of which has to be judiciously selected in order to get 
appropriate and required solute retention. The mobile phase has to be adapted in terms of elution 
strength (solute retention) and solvent selectivity (solute separation). 
Solvent polarity is the key word in chromatographic separations since a polar mobile phase 
will give rise to low solute retention in normal phase and high solute retention in reverse phase LC. 
The selectivity will be particularly altered if the buffer PH is close to thepKaof the analytes; 
the solvent strength is a measure of its ability to pull analyte from the column. It is generally 
controlled by the concentration of the solvent with the highest strength. Buffers, pH of the buffer, 
mobile phase composition are the parameters, which shall be taken into consideration while 
selecting and optimizing the mobile phase.  
Firstly, Buffer and its strength play an important role in deciding the peak symmetries and 
separations. Some of the most, commonly employed buffers are Phosphate buffer (Potassium di 
hydrogen phosphate, Di-potassium hydrogen phosphate, Sodium dihydrogen phosphate, Disodium 
hydrogen phosphate), Phosphoric acid buffers prepared using O-Phosphoric acid, Acetate buffers 
(Ammonium acetate, Sodium acetate) and Acetic acid buffers prepared using acetic acid. 
The retention time[12] also depends on the molar strengths of the buffer. Molar strength is 
increasingly proportional to retention times. The strength of the buffer can be increased, if 
necessary, to achieve the required separations. The solvent strength is a measure of its ability to pull 
analytes from the column. It is generally controlled by the concentration of the solvent with the 
highest strength. Secondly, pH plays an important role in achieving the chromatographic 
separations as it controls the elution properties by controlling the ionization characteristics.  
 Ware conducted using buffers having different pH to obtain the required separations. It is 
important to maintain the pH of the mobile phase in the range of 2.0to8.0 as most columns do not 
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withstand the pH which is outside this range. This is due to the fact that the Siloxane linkage area 
gets cleaved below pH 2.0, while pH valued is above 8.0, silica may dissolve. 
Finally, by choosing the optimum mobile phase[12] composition most of the 
chromatographic separations can be achieved. This is due to the fact that fairly large amount of 
selectivity can be achieved by choosing the qualitative and quantitative composition of aqueous and 
organic portions. Most widely used solvents in reverse phase chromatography are methanol and 
acetonitrile. Experiments were conducted with mobile phases having buffers with different pH and 
different organic phases to check for the best separations between the impurities. A mobile phase 
which gives separation of all the impurities and degrades from the analyte peak and which is rugged 
with variations of both aqueous and organic phase by at least ±0.2% is preferred. 
The low solubility of the sample in the mobile phase can also cause bad peak shapes. It is 
always advisable to use the same solvents for the preparation of sample solution for the preparation 
of sample solution as the mobile phase to avoid precipitation of the compounds in the column 
injector. 
Optimizations are often started only after a reasonable chromatogram has been obtained. A 
reasonable chromatogram means symmetrical peaks in the chromatogram and detection of all the 
compounds. By slight modification of the mobile phase composition, the position of the peaks can 
be predicted within the range of investigated changes. An optimized chromatogram is the one in 
which all the peaks are symmetrical and are well separated in less run time. 
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1.3.6Validation  
The word “validation”[13] means “Assessment” of validity or action of validity or action of 
providing effectiveness’. 
 
1.3.6.1 Definitions 
FDA defines validation as “establish the documented evidence which provides a high of assurance 
that a specific process will consistently produce a product of predetermined specifications and 
quantity attributes”[14]. 
  
WHO action of providing that, any procedure, process, equipment, material, activity, or system 
actually leads to the expected results[15]. 
  
EUMGP define validation as “action of proving in accordance with the principle of Good 
manufacturing practice (GMP), that any material, activity or system actually lead to expected 
result”[15].  
  
AUSTRALIANGMP defines validation as “the action of proving that any material, process, 
activity, procedure, system, equipment or mechanism and intended results”[15]. 
 
1.3.6.2 Method Validation Guidelines 
 Regulatory agencies and European community, Japan and United States published a number 
of guidelines to assist pharmaceutical companies in validation of analytical methods for drug 
substances[13-15]. 
 
Regulatory agencies such as: 
 International Conference on Harmonization (ICH) 
 Food and Drug Administration (FDA) 
 United States Pharmacopoeia (USP) 
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Table 1.2Literature from industrial committees and regulatory agencies 
 
COMMITTEES AND 
REGULATORY AGENCIES 
GUIDELINES AVAILABLE 
ICH 
a) Q2R1guidelines are guidelines for new method   development and 
its validation. 
 
b) Q1R1guidelines are for   development     and   validation of 
stability indicating analytical methods includes methodology. 
USFDA 
Two industry guidelines : 
a) For the validation of analytical methods. 
b) For the validation of bio analytical methods 
IUPAC 
“Harmonized guideline for single laboratory validation of methods of 
analysis. 
EURACHEM 
Detailed guide for method validation   primarily developed for 
ISO/IEC accredited. 
 
Laboratories  but because of its completeness it is also a good source 
For (bio) pharmaceutical laboratories. 
AOAC 
Technical document for the verification of analytical methods for the 
ISO 17025 accreditation. 
Huber 
Has published a technical document for the verification of analytical 
methods for the ISO   17025 accreditation. 
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Table 1.3Comparison of Validation Parameters Required for HPLC Assay Methods 
 
1.3.6.3 Validation Parameters 
 Accuracy 
 The accuracy[14] of an analytical procedure expresses the closeness of agreement between 
the value which is accepted either as a conventional true value or an accepted reference value and 
the value found. 
Accuracy can also be described as the extent to which test results generated by the method 
and the true value agree. 
The ICH document on validation methodology recommends accuracy to be assessed using a 
minimum of nine determinations over a minimum of three concentration levels covering the 
specified range (for example, three concentrations with three replicates each). Accuracy should be 
reported as percent recovery by the assay of known added amount of standard in the sample or as 
the difference between the mean and the accepted true value, together with the confidence Intervals. 
ICH GUIDELINES USP GUIDELINES FDA GUIDELINES 
Accuracy Accuracy Accuracy 
Precision Precision Precision 
Repeatability -- Repeatability 
Inter-day precision -- Inter-day precision 
Reproducibility -- Reproducibility 
Specificity Specificity Specificity 
Limit of detection Limit of detection Limit of detection 
Limit of quantification Limit of quantification Limit of quantification 
Linearity Linearity Linearity 
Range Range Range 
-- Ruggedness -- 
Robustness Robustness Robustness 
System suitability System suitability System suitability 
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Thus, accuracy of the method was studied by recovery experiments using standard addition 
method at three different levels (80%, 100% and 120. Known amounts of Standard solutions 
containing analyte were added to pre-quantified sample solutions to get 80,100 and 120 %.These 
samples were analyzed by injecting the sample solution and % recovery was calculated. In the 
present study %recovery was calculated by the following formula. 
 
 
 
Acceptance limit for % recovery is 98-100% 
 
 Precision: 
 The precision[14] of an analytical procedure expresses the closeness of agreement (degree of 
Scatter) between a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed conditions.  
Precision may be considered at three levels: repeatability, intermediate precision and 
reproducibility. 
Precision is a measure of the reproducibility of the whole analytical method (including 
sampling, Sample preparation and analysis) under normal operating circumstances. Precision is 
determined by using the method to assay a sample for a sufficient number of times to obtain 
statistically Valid results (i.e. between 6 - 1 0). Therefore for present work sample were assayed six 
times and the %RSD for obtained assay values was obtained. Precision is then expressed as the 
Relative Standard Deviation. 
 
 Repeatability: 
 Repeatability[14]expresses the precision under the same operating conditions over a short 
interval of time. Repeatability is also termed intra-assay precision. 
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 Intermediate Precision: 
 Intermediate precision[14] expresses within-laboratories variations; different days, different 
analysts, different equipment, etc. The objective of intermediate precision validation is to verify that 
in the same laboratory the method will provide the same results once the development phases over. 
The objective is also extent to verify that the method will provide the same results in different 
laboratories (ruggedness). 
 
 Reproducibility: 
 Reproducibility[14] expresses the precision between laboratories (collaborative studies, 
usually applied to standardization of methodology). 
 
 Specificity: 
 ICH defines specificity as “the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present. Typically this might include impurities, 
degradants, matrix, etc.”USP<1225>refers to the same definition but also comments that other 
reputable authorities such as IUPAC and AOAC use the term “selectivity” for the same meaning. 
This reserves the use of “specific” for those procedures that produce a response for a single analyte 
only. ISO/IEC most likely has the same understanding because it requires a method to be 
“Selective” rather than specific. Our goal is to distinguish and quantify the response of the target 
compounds from the responses of all other compounds Selectivity is the ability to measure 
accurately and specifically the analyte in the presence of components that may be expected to be 
present in the sample matrix. 
 Specificity[14] for an assay ensures that the signal measured comes from the substance of 
interest and that there is no interference from excipient and/or degradation products and/or 
impurities. Determination of this can be carried out by assessing the peak identity and purity. 
 
 Quantitation: 
 Limit of detection (LOD) and 
 Limit of quantitation (LOQ) study 
 
 Explanation for the LOD and LOQ 
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 Limit of detection: 
 The detection limit[14] of an analytical method is the lowest amount 
which can be detected but not nece
detection limit is the injected amount that results
high as the baseline noise level
three: 
Different methods;  
(i) Visual inspection  
(ii) Standard    deviation of the blank 
(iii) Standard deviation of the response based on the slope of the
 
 Limit of quantitation:
 The quantitation limit[14
which can be quantitated with suitable precision and accuracy.
limit is the minimum injected amount 
with acceptable precision, typically requiring peak heights 10 to 20
noise. Beside this signal/noise method, LOQ can be measured by another three
Different methods;  
(i) Visual inspection  
(ii) Standard deviation of the response 
(iii) Standard deviation of the response based on the slope of the calibration curve.
 
 
ssarily quantitated as an exact value.In chromatography, the 
ina peak with a height atleasttwo
. Besides this signal/noise method, LOD can be measured by another 
response  
 calibration curve.
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 Linearity: 
 The linearity[14] of an analytical procedure is its ability (within a given range) to obtain test 
results which are directly proportional to the concentration (amount) of analyte in the sample. This 
is the method's ability (within a given range) to obtain results which are either directly, or after 
mathematical transformation proportional to the concentration of the analyte within a given range. 
 Linearity is determined by calculating the regression line using a mathematical treatment of 
the results (i.e. least mean squares) vs. analyte concentration. Calibration curve was constructed by 
plotting peak area versus concentrations of analyte. 
 
 Range: 
 The range[14] of an analytical procedure is the interval between the upper and lower 
concentration (Amounts) of analyte in the sample (including these concentrations) for which it has 
been demonstrated that the analytical procedure has a suitable level of precision, accuracy and 
linearity. The range is normally expressed in the same units as the test results. For assay tests, ICH 
requires the minimum specified range to be 80 to 120 percent of the test concentration. 
 
 Robustness: 
 The robustness[14] of an analytical procedure is a measure of its capacity to remain 
unaffected by small but deliberate variations in method parameters and provides an indication of its 
reliability during normal usage. Thus Ruggedness is the degree of reproducibility of results 
obtained by the analysis of the same sample under a variety of normal test conditions i.e. different 
analysts, laboratories, instruments, reagents, assay temperatures, small variations in mobile phase, 
different days etc. (i.e. from laboratory to laboratory, from analyst to analyst.) 
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2.1 ILAPRAZOLE 
 Ilaprazole[16] is a proton pump inhibitor
ulcer disease (PUD), gastroesophag
available in strengths of 5, 10, and 20
CAS registry number (Chemical Abstracts Service): 
Chemical Name : 2-{[(4
yl)-1H
Molecular Formula : C19H18
Chemical structure : 
Molecular weight : 366 
Density  : 1.39g/cm
Category  : Antacid
Sub Category  :Proton pump inhibitor (PPI)
Appearance  : A white to yellow powder
Loss on drying :NMT 0.1%
Sulphated Ash : NMT 0.1%
Storage  :Store protected from light
 
 
2. DRUG PROFILE 
 (PPI) used in the treatment of 
eal reflux disease (GORD/GERD) and 
 mg. 
0172152-36-2 
-Methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl}
-benzimidazole  
N4O2S 
3
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Foreign Names : 
• Ilaprazolum (Latin) 
• Ilaprazol (German) 
• Ilaprazole (French) 
• Ilaprazol (Spanish) 
Brand Names : 
• Noltec 
Ilyang, South Korea 
• Yi Li An 
Livzon Pharma Group, China 
Mechanism of Action: Suppresses gastric basal and suppresses acid secretion by inhibiting the 
parietal cell H+/K+ ATP pump. 
 
Adverse reactions : 
The most common side effects are: 
• Nausea and Vomiting 
• Dizziness 
• Diarrhea 
• Constipation 
• Abdominal Pain 
• Wind and Bloating 
• Skin Rashes 
• Headaches 
Longer Term Side Effects Include: 
• Increase Hip Fracture Risk If Over 50 years Old And On Long Term Treatment 
• More Susceptible To Iron Deficiency Anemia 
• Increased Risk Of Pneumonia In older People 
• Vitamin B12 Deficiency 
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2.2 DOMPERIDONE 
 Domperidone[17] belongs to the class of organic compounds known as benzimidazoles. These 
are organic compounds containing a benzene ring fused to an imidazole ring (five member ring 
containing a nitrogen atom, 4 carbon atoms, and two double bonds). 
 This drug is developed by Janssen Pharmaceutical that acts as a peripherally selective antagonist 
of the dopamineD2 and D3 receptors. It is administered orally, rectally, or intravenously. 
Domperidone is used to relieve nausea and vomiting; to increase the transit of food through the 
stomach (that is, as a prokinetic agent via increasing gastrointestinal peristalsis); and to promote 
lactation (breast milk production) by release of prolactin. It is also used in scientific research to 
study the biological function of dopamine, an important neurotransmitter and hormone, in the body. 
 Domperidone is available in the form of tablets, orally disintegrating tablets (based on Zydis 
technology), suspension and suppositories. 
CAS registry number (Chemical Abstracts Service): 0057808-66-9 
Kingdom  : Organic compounds 
Super class  :Organo heterocyclic compound 
Class   : Benzimidazoles 
Appearance  :A white or almost white powder    
Storage  :Store protected from light 
Brand name  : 
• Motilium 
• MotinormCosti 
• Nomit  
• Brulium 
• Molax 
• Motaline 
• Moperid 
• Monlobia 
• Motidone 
• Motilex 
Chemical Name         : 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-
piperidin-4-   yl}-1,3-dihydro-benzoimidazol-2-one  
Molecular Formula : C22H24ClN5O2 
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Chemical structure :  
 
Molecular weight : 425  
Solubility  : 
 Soluble in 0.1M HCl 
 Slightly soluble in 0.1M NaOH 
 Insoluble in Water 
Category  : Antiemetic agent, Prokinetic agent   
Percentage Purity :≥98%   
Loss on drying :NMT 0.5% 
Half Life  : 7 hours 
Protein Binding : 91% - 93% 
Foreign Names 
• Domperidonum (Latin) 
• Domperidon (German) 
• Domperidone (French) 
• Domperidona(Spanish)
Mechanism of Action: Domperidone is a peripheral dopamine D2 and D3 receptor antagonist. It 
provides relief from nausea by blocking receptors at the chemoreceptor trigger zone (a location in 
the nervous system that mediates nausea) at the floor of the fourth ventricle (a location near the 
brain). It increases motility in the upper gastrointestinal tract to a moderate degree and increases 
lower oesophageal sphincter pressure by blocking dopamine receptors in the gastric antrum and the 
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duodenum. It blocks dopamine receptors in the anterior pituitary gland increasing release of 
prolactin which in turn increases lactation. Domperidone may be more useful in some patients and 
cause harm in others by way of the genetics of the person, such as polymorphisms in the drug 
transporter geneABCB1 (which encodes P-glycoprotein), the voltage-gated potassium 
channelKCNH2 gene (hERG/Kv11.1), and the α1D—adrenoceptorADRA1D gene. 
Adverse reactions : 
 Penetration of immature blood brain barrier. 
 Cardiac side effects 
 Hyperprolactinemia 
 Mastodynia (breast pain/tenderness) 
 Galactorrhea (inappropriate or excessive milk production/secretion 
Uses: 
• Antiemetic 
• Domperidone is useful in diabetic and idiopathic gastroparesis.  
• Domperidone can be used to relieve gastrointestinal symptoms in Parkinson's disease. 
• Functional dyspepsia: Domperidone may be used infunctional dyspepsia in both adults and 
children. 
• Pediatric reflux: Domperidone has been found effective in the treatment of pediatricreflux. 
However some specialists consider it to be an excessively powerful drug for treating babies 
with reflux. 
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3. LITERATURE REVIEW 
P. Venkateswarlu et al., have reported “Determination of Ilaprazole and Domperidone in 
Individual Dosage form Tablets by RP-HPLC”. A simple, sensitive and precise high performance 
liquid chromatographic method for the analysis of Ilaprazole and Domperidone was developed, 
validated and used for the determination of compounds in commercial pharmaceutical products. 
The compounds were well separated an isocratically on a C18 column inertisil C18, 5 μm, [250 mm 
× 4.6 mm] utilizing a mobile phase consisting of acetonitrile: phosphate buffer (60:40, v/v, pH 7.0) 
at a flow rate of 1.0 ml/min with UV detection at 243 nm. The retention time of Ilaprazole and 
Domperidone was found to be 2.543 min and 7.245 min respectively. The method was found 
selective and peaks of Ilaprazole and Domperidone were well separated. The proposed method is 
linear (r2 = 0.999 for Ilaprazole and Domperidone), accurate with 99.5 % recovery for Ilaprazole 
and 99.4 % recovery for Domperidone and precise (% RSD < 1 %). The method was used to 
determine potency of commercial product and potency was found within limit.[18] 
 
SnehaJansari K et al.,have reported “Development and validation of stability indicating method 
for simultaneous estimation of Ciprofloxacin hydrochloride and Tinidazole using RP-UPLC 
method”. The sample was analyzed by reverse phase C18 column (Purospher Star 100×2.1 mm, 
2μm) as stationary phase and Phosphate Buffer: Acetonitrile (80:20) as a mobile phase and pH 3.0 
was adjusted by Orthophosporic acid at a flow rate of 0.3 ml/min. Quantification was achieved of 
Ciprofloxacin HCl at 278.5 nm and of Tinidazole at 317.5 nm with PDA detector. The retention 
time for Ciprofloxacin HCl and Tinidazole was found to be 1.71 and 2.22 minute respectively. The 
linearity for Ciprofloxacin HCl and Tinidazole was obtained in the concentration range of 3.125-
43.75 μg/ml and 3.75-52.5 μg/ml with mean accuracies of 99.77% and 99.75% respectively.[19] 
 
C Rambabu et al.,have reported“Development and Validation of RP-UPLC Method for 
Simultaneous Estimation of Abacavir Sulphate and Lamivudine in Combined Tablet Dosage 
Form”. Chromatographic separations were carried using Acquity BEH C8 (100 mm x 2.1 mm) 1.7 
μm column) with a mobile phase composition of TTriethylamine phosphate buffer (pH 2.5) and 
methanol in the ratio 50:50% (V/V) have been delivered at a flow rate of 0.5 ml min‐1 and the 
detection was carried out using UV detector at wavelength 230 nm. The retention time for 
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Abacavirsulphate and Lamivudine were 0.83 and 1.62 minute respectively. The correlation 
coefficient values in linearity were found to be 0.9999 for both at concentration range 2.509‐50.190 
μg mL‐1 and 20.093 ‐ 401.860 μg mL‐1 respectively. The recovery results were found in the range 
from 99.47‐ 101.08%.[20] 
 
T. Sivakkumar et al., have reported “Development and validation of a rapid-chemo metrics 
assisted RP-HPLC method with PDA detection for the simultaneous estimation of Domperidone 
and Ilaprazole in pure and pharmaceutical formulation”. A simple, rapid, accurate and precise 
chemo metrics assisted RP-HPLC method was developed, optimized and validated for the 
simultaneous estimation of the Domperidone and Ilaprazole in pure and pharmaceutical 
formulation. The developed method was optimized by using Central composite design (CCD) in 
resoponse surface methodology (RSM). Separation of Domperidone and Ilaprazole was achieved on 
phenomenex C18 column (150 X4.6 mm i.d, 5μ particle size) with mobile phase containing 64.89% 
of acetonitrile and 35.11 % of ammonium acetate buffer (14.18mM) was delivered at a flow rate of 
1.2 ml/min. Detection was carried out at 286nm by photodiode array detection. Retention time was 
found to be 1.661 for Domperidone and 2.420 for Ilaprazole. The developed and optimized method 
was validated successfully as ICH guidelines. Linearity of Domperidone and Ilaprazole were found 
to be 30-90μg/ml and 10-30 μg/ml with their correlation coefficient (R2) of 0.9997 and 0.9995 
respectively.LOD and LOQ were found to be 158.12ng/ml and 479.16ng/ml for Domperidone and 
101.68 ng/ml and 308.12ng/ml for Ilaprazole. The % RSD value of accuracy and precision study 
was found to be less than 2 %. Hence this proposed method is useful for the simultaneous 
estimation of Domperidone and Ilaprazole in pure and pharmaceutical dosage form.[21] 
 
Z. N. Patel et al., have reported “RP-HPLC Method for Simultaneous Estimation of Levosulpiride 
and Pantoprazole Sodium in Tablet Dosage Form”. A simple, economic, selective, precise, and 
stability-indicating RP-HPLC method for analysis of Levosulpiride and Pantoprazole sodium was 
developed and validated according to ICH guidelines. The quantification of the drug was carried 
out using Hypercil BDS C18250mm×4.6mm× 5μm or its equivalent in isocratic mode, with mobile 
phase comprising of Water: Acetonitrile: Triethylamine (60: 40: 0.25 v/v/v) the flow rate was 
1ml/min and the detection was carried at 225 nm. The retention time for Levosulpiride and 
Pantoprazole sodium was found to be 3.597 and 5.147min respectively. The percentage assay for 
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Levosulpiride and Pantoprazole sodium was found to be 99.56% and 98.44% respectively. The 
method was also applied for the determination of Levosulpiride and Pantoprazole sodium in the 
presence of their degradation products formed under variety of stress conditions. Proposed method 
was validated for precision, accuracy, linearity range, specificity and robustness.[22] 
 
Umadurai M et al., have reported “Development and validation of a rapid UPLC Assay method 
for the simultaneous estimation of Paroxetine and Clonazepam in tablet dosage form”. 
Chromatographic separation was performed on Thermofischer scientific Hypercel C18 column (50x 
2.1mm,1.8μm) column with mobile phase comprising of mixture of Acetonitrile: Methanol: 
Potassium di hydrogen orthophosphate buffer (8:52:40 )buffer (pH 3, adjusted with Ortho 
phosphoric acid) at the flow rate 0.5 ml/min. The detection was carried out at 265 nm. The retention 
times of Paroxetine and Clonazepam were found to be 1.28 and 2.45 mins respectively with a run 
time of 4 mins, theoretical levels for Paroxetine and Clonazepam were 4144and 5067 respectively, 
with a resolution of 8.09.[23] 
 
Sevak Manan R et al., have reported “Development& validation of RP-UPLC method for 
simultaneous estimation of Ofloxacin and Ornidazole in their combine dosage form including stress 
study”. The sample was analyzed by RP-UPLC instrument using reverse phase C18 column 
(Purospher Star 100×2.1 mm, Merck Specialities) as stationary phase and Phosphate Buffer: 
Acetonitrile (70:30 v/v) as a mobile phase [where PH of the buffer was adjusted to 2.5 by using Tri 
ethyl amine (1ml / lit buffer) and Orthophosphoric acid at a flow rate of 0. 4 ml/min. TUV detector 
was used for the detection at 294 nm. The retention time for Ofloxacin and Ornidazole was found to 
be 0.648 and 1.158 minute respectively. The linearity for both the drugs was obtained in the 
concentration range of 2-14 μg/ml and 5-35 μg/ml.[24] 
 
ParamasivamBalan et al., have reported “Development and validation of stability-indicating RP-
UPLC method for simultaneous estimation of Thiocolchicoside and Aceclofenac in combined 
dosage form”. The chromatographic separation was carried out by Thermo Scientific UPLC 
Instrument, Accela 1250 Pump, auto sampler with PDA detector, using column Thermo 
ScientificHypersil gold C18, (50 x 2.1mm) particle size 1.9μm using 5% ammonium acetate buffer 
and methanol in the ratio of 40:60, pH was adjusted to 5 with Orthophosphoric acid as mobile phase 
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at a flow rate of 250 μl/min with the detection at 276nm. The run times of the TCC and ACF were 
about 0.697 and 1.125 minutes, respectively. The detector response is linear from 4.8 μg/mlto 7.2 
μg/ml and 63.8 μg/ml to 96 μg/ml concentrations for TCC and ACF respectively. The detection 
limit and quantification limit was 0.076μg and 0.23μg for TCC and 0.27μg and 0.71μg for ACF. 
The percentage of assay of TCC and ACF were about 99.50% and 99.96% respectively.[25] 
R.A Tamboliet al., have reported “Development and Validation of RP-HPLC Method for 
Simultaneous Estimation of Ilaprazole and Domperidone in Pharmaceutical Dosage Form”. A 
specific,  accurate,  precise  and  reproducible  RP-HPLC  method  was  developed  and 
subsequently validated for the simultaneous determination of Ilaprazole and Domperidone  in 
pharmaceutical dosage form. The proposed HPLC method utilizes Hypersil (Thermo scientific) C18 
column (250 mm × 4.6 mm id, 5 μm particle size), and mobile phase consisting of 
methanol:phosphate buffer (40:60) and pH adjusted to 4.0 with 0.1M glacial acetic acid at a flow 
rate of 1.0 ml/min. Quantitation was achieved with UV detection at 230 nm based on peak area with 
linear calibration curves at concentration ranges 5-15 μg/ml for Ilaprazole and 15-45 μg/ml for 
Domperidone. The retention time of Ilaprazole and Domperidone were found to be 3.433 min and 
5.860 min respectively. The method was validated in terms of accuracy, precision, linearity, 
limits of detection, limits of quantitation and robustness. This method has been successively applied 
to marketed formulation and no interference from the formulation excipients was found.[26] 
Pradeep G. Shelke et al.,have reported “Validated Stability-indicating assay method for 
determination of Ilaprazole in bulk drug and tablets by high performance liquid chromatography”. 
A validated stability-indicating HPLC method was reported for the determination of Ilaprazole in 
bulk drug and tablet. The drug was subjected to the various stress conditions as per the ICH 
guidelines. The degradation behavior of Ilaprazole was studied under hydrolytic, oxidative, 
photolytic and thermal conditions and was found to be unstable in almost all conditions except 
under alkaline and photolytic conditions. The separation of drug and its degraded products was 
carried out on Kinetex C- 18 100A (5μ, 250×4.6 mm) column. The initial mobile phase 
composition used was Acetonitrile and water in the ratio 50:70v/v for 1 min then changed to 
70:30v/v in next 6 min and finally equilibrated back to initial composition in 14min. The method 
was applied for the determination of Ilaprazole in marketed tablet formulation. The detection was 
carried at 305 nm using PDA detector with a flow rate of 1.0ml/min and injection volume 20μl. The 
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validation of developed method was performed for linearity, accuracy, precision, selectivity and 
specificity and robustness.[27] 
 
Darshil B. Shah et al., have reported in a review article “Analytical method for determination of 
proton pump inhibitors in bulk and indifferent dosage forms”. Proton pump inhibitor is very 
effectively used in gastric disorder for reducing acid secretion. They very potent in nature and used 
only after therapy with histamine-2 (H2) receptor antagonists, known as H2 blockers, have been 
unsuccessful for symptoms of reflux. PPIs are inactivated by exposure to gastric acid, due to rapid 
degradation of these drugs in acidic and aqueous media, it is challenging to develop analytical 
method where in stability of drug is least hampered. This review entitles different methods 
developed for determination of PPIs like UV-Spectroscopy, liquid Chromatography and LC-MS.[28] 
Kamala Govinda Rao et al., have reported “Method Development and Validation for Simultaneous 
Estimation of Omeprazole and Domperidone by RP-HPLC”. The developed RP-HPLC method 
allows rapid and precise determinations of Omeprazole and Domperidone, the scope of the present 
work was to expand and optimization of the chromatographic conditions, to develop RP-HPLC 
method. A series of mobile phases were tried, among the various mobile phases as methanol and 
0.1% ammonium acetate an ideal mobile phase, since it gave a good resolution and peak shapes 
with perfect optimization. The flow rate was optimized at 1 ml/min. The linearity and correlation 
coefficient of Omeprazole and Domperidone were found to be 10–50 ug/ml, and 10.10–50.50 ug/ml 
0.9996, and 0.998 respectively. The limit of detection for Omeprazole and Domperidone was found 
to be 1.76 and 2.0 and the limit of quantification was found to be 1.87 and 1.48. The method was 
known to be accurate with the assay method. The % assay was found to be 97 and 98.12. The 
developed method was showed to a good accuracy and precision. The % RSD is for Omeprazole 
and Domperidone is 041 and 1.41. The Isocratic elution technique developed for the determination 
of Omeprazole and Domperidone ideally suited for rapid and routine analysis. This method shows 
that good reproducibility of the results. Furthermore this method was simple, sensitive, and 
accurate. Degradation studies were done, here the drug stability results were in the range of 
acceptance criteria 85–115%.[29] 
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4. AIM AND PLAN OF WORK 
4.1 AIM 
To develop and validate a new method for the simultaneous determination of Ilaprazole and 
Domperidone in capsule dosage form by Ultra Performance Liquid Chromatography [UPLC]. 
 
4.2 OBJECTIVE 
The literature review revealed that there are several methods reported for the estimation 
Ilaprazole and Domperidone alone or in combination with other drugs in their pharmaceutical 
dosage forms but none of the method available for the estimation of these drugs in the selected 
pharmaceutical dosage form by this intended method (UPLC). 
It is common to administer two or more drugs in a single formulation and it may be to 
reduce the number of medicaments to be taken at a time for better patient compliance.  It is a 
challenging task for the analyst to develop a simple analytical method for simultaneous estimation 
of multiple drug formulations with desired degree of accuracy and precision. In the present work 
attempts have been made to develop Rapid UPLC method of analysis for a simultaneous estimation 
of selected two drugs in capsule dosage form. 
Hence on the basis of the literature survey, it was thought to develop a precise, accurate, 
simple, rapid and reliable method for estimation of Ilaprazole and Domperidone in capsules dosage 
form using the following technique of UPLC.  
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4.3 PLAN OF WORK 
Plan of work was designed as follows: 
I. Literature collection.   
II. Study of physicochemical properties of drug (pH, pKa and solubility). 
III. Procurement of chemicals and API. 
IV. Method development and optimization of chromatographic conditions 
 Selection of diluent 
 Selection of wavelength 
 Choice of chromatographic method 
 Selection of initial separation 
 Optimize the chromatographic variables. 
V. Development of UPLC method for the quantification of Ilaprazole and Domperidonein 
capsules dosage form. 
VI. Validation of proposed method as per ICH Q2 (R1) guidelines. 
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5. MATERIALS AND EQUIPMENTS 
 
5.1 INSTRUMENTS USED 
 
Table 5.1: List of instruments used during validation studies 
Sl. 
No. Instruments Name Model 
01 UV- Visible Spectrophotometer Shimadzu 1800 
02 UPLC with PDA detector Thermo scientific 
03 Analytical Balance Metler 
04 pH meter Eutech 
05 Ultra Sonicator Remi Instrument Ltd 
06 Pipettes and Burettes Borosil (Class A) 
07 Glass Beakers Borosil 
08 Measuring Cylinder Borosil 
09 Volumetric( Standard) Flask Borosil (Class A) 
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5.2 DRUGS AND CHEMICALS USED 
 Ilaprazole and Domperidone was obtained from Aeon Formulations Pvt. Ltd.(Puducherry, 
India) as gift sample and marketed formulation Ilavieon DSR capsules(Ilaprazole 10 mg and 
Domperidone30mg) manufactured by Aeon Formulations Pvt. Ltd. was procured form local 
market of Chennai. 
Table 5.2: List of chemicals used during validation studies 
Sl 
No. Materials Manufacturer 
Batch no/ 
Control No 
01 Triethylamine MERCK SF3S630365 
02 Ammonium acetate MERCK QE4Q641100 
03 Phosphoric acid MERCK PM2P523951 
04 Acetic acid MERCK CJ4C640904 
05 Methanol HIMEDIA MET/1510032 
06 Acetonitrile MERCK DL4DF41617 
07 HPLC water MILLI-Q 112871 
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6. ANALYTICAL METHOD DEVELOPMENT 
AND OPTIMIZTION 
 
 A good method development strategy should require only as many experimental runs as are 
necessary to achieve the desired final result. Finally method development should be as simple as 
possible, and it should allow the use of sophisticated tools such as computer modelling. The 
important factors, which are to be taken into account to obtain reliable quantitative analysis, are 
 Careful sampling and sample preparation. 
 Precise sample injection. 
 Appropriate choice of the column. 
 Choice of the operating conditions to obtain the adequate resolution of  mixture. 
 Reliable performance of the recording and data handling systems. 
 Suitable integration/peak height measurement techniques. 
 The mode of calculation best suited for the purpose. 
 Validation of the developed method.  
Stock Solution A(Ilaprazole) 
Weighed accurately about 20.03 mg of Ilaprazole and transferred it to a 50 ml standard flask and 
sufficient methanol was added to dissolve it. Then the solution was sonicated for 10 minutes and 
made the volume up to the mark with methanol. Final concentration was 400.6μg/ml. 
Stock Solution B (Domperidone)  
Weighed accurately about 61.18mg of Domperidone and transferred it to a 50 ml standard flask and 
sufficient methanol was added to dissolve it. Then the solution was sonicated for 10 minutes and 
made the volume up to the mark with methanol. Final concentration was 1223.6μg /ml. 
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Standard Solution Preparation 
1 ml of stock solution A and 1
standard flask. This was then diluted with 30 ml of 
with same solvent. This was marked and labelled as 
of Ilaprazole and 12.236μg/ml of 
membrane filter. 
Selection Of Wavelength 
 The sensitivity of the UPLC method that uses PDA detection depends upon the proper 
selection of the wavelength. An ideal wavelength is one that gives good response for the drugs to be 
detected. In the entire UV visible region both the drugs were strongly a
wavelength was selected for further studies. 
Wavelength Selection of Combined Drugs (Domperidone and Ilaprazole)
 
 
 
 
 
 
 
 
 ml of stock solution B were mixed in a 10
methanol. The volume was made up to 
standard solution which 
Domperidone. Resulting solution was then filtered with 0.45 µ 
(λmax) 
bsorbed 
 
C 
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0 ml dried and cleaned 
100 ml 
contains 4.006 μg/ml 
at 288 nm. So this 
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6.1 Development of RP-UPLC method for Ilaprazole and Domperidone 
Trial 1 
Chromatographic condition 
Mobile phase  :   0.5% W/V of Ammonium acetate : Methanol (50:50) 
Column  :   C18(50 X 2.1 mm, 1.9 µm) 
Diluent  :  Methanol 
Flow rate  :  0.4ml/min 
Run time  :  5 min 
Injection volume :  5µl 
Column temperature :  Ambient 
PDA Detection :  288 nm 
Instrument Make  : Thermo 
Mode   : Accela 1250 
Software  :  Chroquest 5.0 
 
Figure 6.1: Trial chromatogram 1 for Ilaprazole and Domperidone 
Observation: From the above chromatogram it was observed that the Ilaprazole peak was splitted 
and the shape of Domperidone peak is not good.  Hence this trial is not suitable. 
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Chromatographic condition 
Mobile phase  :   P
  Methanol (60:40)
Column  :   C18(50 X 2.1 mm, 1.9 
Diluent  :  Methanol
Flow rate  :  0.4ml/min
Run time  :  4 min
Injection volume :  10
Column temperature :  Ambient
PDA Detection :  288 nm
Instrument Make  : Thermo
Mode   : Accela 1250
Software  :  Chroquest 5.0
Figure 6.2: Trial chromatogram 
Observation: From the above peak it was observed that 
of Domperidone
 
Trial 2 
hosphoric acid (pH adjusted to 3.5 with Triethylamine
 
µm) 
 
 
 
µl 
 
 
 
 
 
2 for Ilaprazole and Domperidone
Ilaprazole peak was splitted and the shape 
 peak is not good. Hence this trial is not suitable.
 
 
C 
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Chromatographic condition 
Mobile phase  :   Water : Methanol(30:20) 
  Triethylamine
Column  :   C18(50 X 2.1 mm, 1.9 
Diluent  :  Methanol
Flow rate  :  0.4ml/min
Run time  :  4 min
Injection volume :  10
Column temperature :  Ambient
PDA Detection :  288 nm
Instrument Make  : Thermo
Mode   : Accela 1250
Software  :  Chroquest 5.0
 
Figure 6.3: Trial chromatogram 
Observation: From the above chromatogram it was observed that the 
Hence this trial is not suitable.
 
TRIAL 3 
finally adjust the pH to 5.0 with 
 
µm) 
 
 
 
µl 
 
 
 
 
 
3 for Ilaprazole and Domperidone
Ilaprazole peak is not eluted
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Trial 4 
Chromatographic condition 
Mobile phase  :   Water : Methanol : ACN : Acetic Acid (30:20:50:0.3) finally adjust 
  the pH to 5.0 with Triethylamine 
Column  :   C18(50 X 2.1 mm, 1.9 µm) 
Diluent  :  Methanol 
Flow rate  :  0.4ml/min 
Run time  :  3 min 
Injection volume :  10µl 
Column temperature :  Ambient 
PDA Detection :  288 nm 
Instrument Make  : Thermo 
Mode   : Accela 1250 
Software  :  Chroquest 5.0 
Figure 6.4: Trial chromatogram 4 for Ilaprazole and Domperidone 
DRUG 
RETENTION 
TIME 
AREA 
AREA 
% 
THEORETICAL 
PLATES (USP) 
RESOLUTION 
(USP) 
ASYMMETRY 
DPD 0.598 145852 32.27 2249 0.00 1.70 
IPZ 2.072 306090 67.73 2589 16.81 1.85 
Total  451942 100.00    
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Observation: From the above chromatogram it was observed that DPD and IPZ are well separated. 
Retention time of DPD and IPZ are 0.598 and 1.072 minute respectively. So this method was found 
as optimized method and selected for further analysis. 
Optimized Analytical Method  
Four trials were performed by changing the different parameters like flow rate, injection volume 
mobile phase etc. From the above four trails it has been observed that trial 4 is optimized method to 
carry out the validation of IPZ and DPD in marketed capsule formulation. Optimized 
chromatographic parameters are given below. 
Chromatographic condition 
Mobile phase  :   Water : Methanol : ACN : Acetic Acid (30:20:50:0.3) finally adjust 
  the pH to 5.0 with Triethylamine 
Column  :   C18(50 X 2.1 mm, 1.9 µm) 
Diluent  :  Methanol 
Flow rate  :  0.4ml/min 
Run time  :  3 min 
Injection volume :  10µl 
Pump Mode  : Isocratic 
Column temperature :  Ambient 
PDA Detection :  288 nm 
Instrument Make  : Thermo 
Mode   : Accela 1250 
Software  :  Chroquest 5.0 
 
6.2 Quantitative Estimation of Ilaprazole and Domperidone 
System suitability  
This parameter was tested by giving five replicate injections of the standard solution to check the 
system suitability parameters like asymmetry, theoretical plates, tailing factor etc. Weight taken for 
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stock solution A & B were 51.28 mg of IPZ and 12.65 mg of DPD respectively. Suitability 
parameters were calculated and given in table6.1& 6.2. 
Figure 6.5: Chromatogram of System Suitability of Standard, Replicate Injection 01 
Figure 6.6: Chromatogram of System Suitability of Standard, Replicate Injection 02 
 
 
Figure 6.7: Chromatogram of System Suitability of Standard, Replicate Injection 03 
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Figure 6.8: Chromatogram of System Suitability of Standard, Replicate Injection 04 
 
Figure 6.9: Chromatogram of System Suitability of Standard, Replicate Injection 05 
Table 6.1: Results of System Suitability Domperidone 
INJECTION ID 
RETENTION 
TIME 
AREA THEORETICAL 
PLATES ( USP) ASYMMETRY 
1 0.600 149623 2264 1.69 
2 0.598 149725 2264 1.68 
3 0.600 149841 2263 1.66 
4 0.600 148468 2268 1.73 
5 0.602 149101 2265 1.71 
AVERAGE 
 
149352 2264.80 1.69 
STD DEV 
 
569 
  
% RSD 
 
0.381 
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Table 6.2: Results of System Suitability Ilaprazole 
INJECTION ID 
RETENTION 
TIME 
AREA THEORETICAL 
PLATES ( USP) ASYMMETRY 
1 2.077 306754 2624 1.82 
2 2.072 309482 2609 1.80 
3 2.077 309371 2616 1.77 
4 2.067 309673 2607 1.88 
5 2.077 308925 2644 1.84 
AVERAGE 
 
308841 2620 1.82 
STD DEV 
 
1199 
  
% RSD 
 
0.388 
  
 
Acceptance Criteria : Asymmetry NMT 2.0 
    Theoretical plates NLT 2000 
    RSD of area NMT 2.0 
Report  : The all system suitability parameters for IPZ and DPD were found  
  within limits. 
Linearity and Range  
 The linearity of an analytical procedure is its ability (within a given range) to obtain test 
results which are directly proportional to the concentration (amount) of analyte in the sample. To 
demonstrate the linearity of analytes over the range 80% to 120% of target concentration five 
different concentration solutions of the DPD & IPZ (80%, 90%, 100%, 110%, and 120%) prepared 
and take injections in UPLC by the means of auto injector. 
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Procedure 
Stock Solution A (Ilaprazole) 
  Weighed accurately about 20 mg of Ilaprazole and transferred it to a 50 ml standard 
flask and sufficient methanol was added to dissolve it. Then the solution was sonicated for 
10 minutes and made the volume up to the mark with methanol. Final concentration was 
400μg/ml. 
Stock Solution B (Domperidone)  
  Weighed accurately about 60 mg of Domperidone and transferred it to a 50 ml 
standard flask and sufficient methanol was added to dissolve it. Then the solution was 
sonicated for 10 minutes and made the volume up to the mark with methanol. Final 
concentration was 1200 μg /ml. 
Actual weight taken, 
For stock solution A (Ilaprazole) =  20.03 mg 
For stock solution B (Domperidone) = 61.18 mg 
 
Preparation of 80% Solution: 
Dilute 0.8 ml of stock solution A and 0.8 ml of stock solution B in 100 ml volumetric flask and 
make up the volume up to the mark with same diluent. 
 
Preparation of 90% Solution: 
Dilute 0.9 ml of stock solution A and 0.9 ml of stock solution B in 100 ml volumetric flask and 
make up the volume up to the mark with same diluent. 
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Preparation of 100% Solution: 
 
Dilute 1 ml of stock solution A and 1 ml of stock solution B in 100 ml volumetric flask and make 
up the volume up to the mark with same diluent. 
 
Preparation of 110% Solution: 
 
Dilute 1.1 ml of stock solution A and 1.1 ml of stock solution B in 100 ml volumetric flask and 
make up the volume up to the mark with same diluent. 
 
Preparation of 120% Solution: 
 
Dilute 1.2 ml of stock solution A and 1.2 ml of stock solution B in 100 ml volumetric flask and 
make up the volume up to the mark with same diluent. 
Figure 6.10: Chromatogram of linearity solution (80%) 
DRUG 
RETENTION 
TIME 
AREA 
AREA 
% 
THEORETICAL 
PLATES (USP) 
RESOLUTION 
(USP) 
ASYMMETRY 
DPD 0.603 115657 32.29 2282 0.00 1.73 
IPZ 2.078 242560 67.71 2695 16.76 1.85 
Total  358217 100.00    
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Figure 6.11: Chromatogram of linearity solution (90%) 
 
Figure 6.12: Chromatogram of linearity solution (100%) 
 
Figure 6.13: Chromatogram of linearity solution (110%) 
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Figure 6.14: Chromatogram of linearity solution (120%) 
 
 
Table 6.3: Linearity results for Domperidone and Ilaprazole 
SL. NO LINEARITY LEVEL DOMPERIDONE (DPD) ILAPRAZOLE (IPZ) 
  
CONCENTRATION 
(µg/ml) AREA 
CONCENTRATION 
(µg/ml) AREA 
1 80% 9.79 115657 3.20 242560 
2 90% 11.01 131110 3.61 275505 
3 100% 12.24 145029 4.01 302861 
4 110% 13.46 159996 4.41 331534 
5 120% 14.68 174431 4.81 362008 
Correlation coefficient 0.999 0.999 
Slope 11973 73371 
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Figure 6.15: Calibration graph of Domperidone 
 
Figure 6.16: Calibration graph of Ilaprazole 
Acceptance criteria: Correlation coefficient ≥ 0.997 
Report: The relationship between the concentration and the peak response of Domperidone 
(DPD) and Ilaprazole (IPZ) were found linear in the specific range and regression 
coefficient for both Domperidone and Ilaprazole was found to be 0.999. 
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Assay of Ilaprazole and Domperidone in Capsule Dosage Form 
Preparation of Standard Solution 
Stock Solution A (Ilaprazole) 
   Weighed accurately about 20 mg of Ilaprazole and transferred it to a 50 ml standard 
flask and sufficient methanol was added to dissolve it. Then the solution was sonicated for 10 
minutes and made the volume up to the mark with methanol. Final concentration was 
400μg/ml. 
Stock Solution B (Domperidone)  
  Weighed accurately about 60 mg of Domperidone and transferred it to a 50 ml 
 standard flask and sufficient methanol was added to dissolve it. Then the solution was 
 sonicated for 10 minutes and made the volume up to the mark with methanol. Final 
 concentration was 1200μg /ml. 
 Standard Solution Preparation  
  1 ml of stock solution A and 1 ml of stock solution B were mixed in a 100 ml dried 
 and  cleaned standard flask. This was then diluted with 30 ml of methanol. The volume 
 was  made up to 100 ml with same solvent. This was marked and labelled as standard 
 solution which contains 4.006 μg /ml of Ilaprazole and 12.00μg/ml of  Domperidone. 
 Resulting solution was then filtered with 0.45 µ membrane filter. 
Preparation of Sample Solution 
  Twenty capsules were accurately weighed and the content of the shell were removed 
completely to a clean and dried petri plate.Clean inside of the shells and the empty capsule 
shells were weighed accurately. Average weight of the powder for 20 capsules was 
calculated. A quantity of powder weigh equivalent to 10 mg of IPZ and 30 mg of DPD was 
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weighed and transferred to a 25 ml volumetric flask and sufficient diluent was added to 
dissolve it. Then the solution was sonicated for 10 min. Final volume was adjusted with the 
same solvent and filtered through 0.45 µ membrane filter. 1 ml of the solution was pipetted 
out in a 100 ml dried and cleaned standard flask. This was then diluted with 30 ml of 
methanol. The volume was made up to 100 ml with same solvent. Resulting solution was 
then filtered through 0.45 µ membrane filter. The sample solution contains 4µg/ml of 
Ilaprazole and 12 µg/ml of Domperidone. 
Procedure:  
 Standard and sample solution were loaded on vial and injected into the chromatographic 
system with the help of auto injector separately. Injection has to be carried out by 5 replication of 
standard followed by sample. 
Average weight of 20 capsules =  320.0 mg 
Weight taken = 316.18 mg 
Label claim: 10 mg of Ilaprazole 
  30 mg of Domperidone  
Purity of Working Standard purity 
  Ilaprazole : 99.48% 
  Domperidone : 99.22% 
Weight taken for standard Solution  
Ilaprazole : 20.03 mg 
  Domperidone : 61.18 mg 
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Figure 6.17: Chromatogram of Sample (Marketed Capsule)  
DRUG 
RETENTION 
TIME 
AREA 
AREA 
% 
THEORETICAL 
PLATES (USP) 
RESOLUTION 
(USP) 
ASYMMETRY 
DPD 0.598 149725 32.27 2249 0.00 1.70 
IPZ 2.072 306090 67.73 2589 16.75 1.85 
Total  451942 100.00    
 
Calculation: 
The amount of Ilaprazole and Domperidone present in each capsule were calculated by using the 
following formula: 
 	

 
=
Sample Area
Standard Area
 X 
Standard  weight
Standard  Dilution
 X 
Sample Dilution
Sample weight
X
WS purity
100
 X Average weight 
%& =
Amount present
Label Claim
 X 100 
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Table 6.4: Tabular column for the assay of Capsule sample 
Sl. 
No 
Drug 
Name 
Sample 
Area 
Standard 
Area 
Label claim 
(mg) 
Amount Present 
(mg) 
Assay 
% 
1 DPD 145831 149352 30 29.99 99.98 
2 IPZ 306090 308841 10 10.00 100.00 
 
Report:   The percentage purity of Domperidone and Ilaprazole were calculated in capsule dosage 
form and it was found to be 102.53 % and 100.00 % respectively. 
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7. VALIDATION OF DEVELOPED METHOD 
7.1 PREPARATION OF SOLUTION 
7.1.1 Preparation of mobile phase 
 Water, Methanol, Acetonitrile and Acetic acid were mixed in the ratio of 
30:20:50:0.3andthe pH was adjusted to 5.0 with Triethylamine. Sonicated the solution by the help 
of ultra sonicator for 20 minutes and filtered with 0.45 µ membrane filter. 
7.1.2 Preparation of working standard solution 
Stock Solution A (Ilaprazole) 
   Weighed accurately about 20 mg of Ilaprazole and transferred it to a 50 ml standard 
flask and sufficient methanol was added to dissolve it. Then the solution was sonicated for 10 
minutes and made the volume up to the mark with methanol. Final concentration was 
400μg/ml. 
Stock Solution B (Domperidone)  
  Weighed accurately about 60mg of Domperidone and transferred it to a 50 ml 
 standard flask and sufficient methanol was added to dissolve it. Then the solution was 
 sonicated for 10 minutes and made the volume up to the mark with methanol. Final 
 concentration was 1200μg /ml. 
7.1.3 Standard Solution Preparation  
 1 ml of stock solution A and 1 ml of stock solution B were mixed in a 100 ml dried and 
cleaned standard flask. This was then diluted with 30 ml of methanol. The volume was made up to 
100 ml with same solvent. This was marked and labelled as standard stock solution which contains 
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4.006μg /ml of Ilaprazole and 12.00μg/ml of Domperidone. Resulting solution was then filtered 
with 0.45 µ membrane filter. 
6.1.4 Preparation of Sample solutions 
 Twenty capsules were accurately weighed and the content of the shell were removed 
completely to a clean and dried petri plate.Clean inside of the shells and the empty capsule shells 
were weighed accurately. Average weight of the powder for 20 capsules was calculated.A quantity 
of powder weigh equivalent to 10mg of IPZ and 30 mg of DPD was weighed and transferred to a25 
ml volumetric flask and sufficient diluent was added to dissolve it. Then the solution was sonicated 
for 10 min. Final volume was adjusted with the same solvent and filtered through 0.45 µ membrane 
filter. 1 ml of the solution was pipetted out in a 100 ml dried and cleaned standard flask. This was 
then diluted with 30 ml of methanol. The volume was made up to 100 ml with same solvent. 
Resulting solution was then filtered through 0.45 µ membrane filter. 
 The sample solution contains 4µg/ml of Ilaprazole and 12µg/ml of Domperidone. The 
amount of Ilaprazole and Domperidone present in each capsule were calculated by using the 
following formula: 
Amount present 
=
Sample Area
Standard Area
 X 
Standard  weight
Standard  Dilution
 X 
Sample Dilution
Sample weight
X
Percentage purity
100
 X Average weight 
% Amount present =
Amount present
Label Claim
 X 100 
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7.2 ANALYTICAL METHOD VALIDATION 
The developed method was validated according to ICH guidelines 
 
Method validation of Ilaprazole and Domperidone  
The mobile phase was prepared and all parameters were set as per the above optimized method. 
7.2.1 Specificity 
 Specificity is the ability to assess unequivocally the analyte in the presence of components 
which may be expected to be present. The specificity of the method was evaluated with regard to 
interference due to presence of any other excipients. The figure shows that drug was clearly 
separated from its excipients. Thus, the UPLC method presented in this study is selective. 
 Lack of specificity of an individual analytical procedure may be compensated by other 
supporting analytical procedures. 
Identification of Ilaprazole and Domperidone: Solutions of standard and Sample were prepared 
as per test method and injected into the chromatographic system.  
Acceptance criteria: Chromatogram of Standard and sample should be identical with near /same 
retention time.  
Blank interference: A study to establish the interference, blank detection was conducted. Mobile 
phase was injected as per the test method.  
Acceptance criteria: Chromatogram of blank did not show any peak at the retention time of 
analyte peak. 
The blank, standard solution and sample solution were loaded on vial and chromatogram was 
recorded. 
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Figure 7.2
DRUG 
RETENTION 
TIME 
AREA
IPZ 2.077 332450
Figure 
 
Figure 7.1: Chromatogram of blank 
 
: Chromatogram of Ilaprazole (WS) 
 
AREA 
% 
THEORETICAL 
PLATES (USP) 
RESOLUTION
(USP)
 100 2570 0.00
 
7.3: Chromatogram of Domperidone (WS)
C 
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ASYMMETRY 
 1.82 
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DRUG 
RETENTION 
TIME 
AREA 
AREA 
% 
THEORETICAL 
PLATES (USP) 
RESOLUTION 
(USP) 
ASYMMETRY 
DPD 0.600 143549 100 2244 0.00 1.68 
 
 
Figure 7.4: Chromatogram of sample solution 
DRUG 
RETENTION 
TIME 
AREA 
AREA 
% 
THEORETICAL 
PLATES (USP) 
RESOLUTION 
(USP) 
ASYMMETRY 
DPD 0.600 149841 32.63 2263 0.00 1.66 
IPZ 2.077 309371 67.37 2616 16.78 1.77 
Total  459212 100.00    
 
 
Report :  Chromatogram of blank did not show any peak at the retention time of analytepeak 
 and retention time of standard and sample were identical. 
7.2.2 System suitability  
This parameter was tested by giving five replicate injections of the standard solution to check the 
system suitability parameters like asymmetry, theoretical plates, tailing factor etc. Weight taken for 
stock solution A & B were 51.28 mg of IPZ and 12.65 mg of DPD respectively. Suitability 
parameters were calculated and given in table 7.1 & 7.2. 
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Figure 7.5: Chromatogram of System Suitability of Standard, Replicate Injection 01 
 
Figure 7.6: Chromatogram of System Suitability of Standard, Replicate Injection 02 
 
Figure 7.7: Chromatogram of System Suitability of Standard, Replicate Injection 03 
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Figure 7.8: Chromatogram of System Suitability of Standard, Replicate Injection 04 
 
 
Figure 7.9: Chromatogram of System Suitability of Standard, Replicate Injection 05 
 
Table 7.1: Results of System Suitability Domperidone 
INJECTION ID 
RETENTION 
TIME 
AREA THEORETICAL 
PLATES ( USP) ASYMMETRY 
1 0.600 149623 2264 1.69 
2 0.598 149725 2264 1.68 
3 0.600 149841 2263 1.66 
4 0.600 148468 2268 1.73 
5 0.602 149101 2265 1.71 
AVERAGE 
 
149352 2264.80 1.69 
STD DEV 
 
569 
  
% RSD 
 
0.381 
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Table 7.2: Results of System Suitability Ilaprazole 
INJECTION ID 
RETENTION 
TIME 
AREA THEORETICAL 
PLATES ( USP) ASYMMETRY 
1 2.077 306754 2624 1.82 
2 2.072 309482 2609 1.80 
3 2.077 309371 2616 1.77 
4 2.067 309673 2607 1.88 
5 2.077 308925 2644 1.84 
AVERAGE 
 
308841 2620 1.82 
STD DEV 
 
1199 
  
% RSD 
 
0.388 
  
 
Acceptance Criteria : Asymmetry NMT 2.0 
    Theoretical plates NLT 2000 
    RSD of area NMT 2.0 
Report  : The all system suitability parameters for IPZ and DPD were found  
  within limits. 
7.2.3 Assay of Ilaprazole and Domperidone in Capsule Dosage Form 
7.2.3.1 Preparation of Standard Solution 
Stock Solution A (Ilaprazole) 
   Weighed accurately about 20 mg of Ilaprazole and transferred it to a 50 ml standard 
flask and sufficient methanol was added to dissolve it. Then the solution was sonicated for 10 
minutes and made the volume up to the mark with methanol. Final concentration was 
400μg/ml. 
Stock Solution B (Domperidone)  
  Weighed accurately about 60mg of Domperidone and transferred it to a 50 ml 
 standard flask and sufficient methanol was added to dissolve it. Then the solution was 
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 sonicated for 10 minutes and made the volume up to the mark with methanol. Final 
 concentration was 1200μg /ml. 
 Standard Solution Preparation  
  1 ml of stock solution A and 1 ml of stock solution B were mixed in a 100 ml dried 
 and cleaned standard flask. This was then diluted with 30 ml of methanol. The volume 
 was made up to 100 ml with same solvent. This was marked and labelled as standard  
 solution which contains 4.006 μg /ml of Ilaprazole and 12.00μg/ml of  Domperidone. 
 Resulting solution was then filtered with 0.45 µ membrane filter. 
7.2.3.2 Preparation of Sample Solution 
  Twenty capsules were accurately weighed and the content of the shell were removed 
completely to a clean and dried petri plate.Clean inside of the shells and the empty capsule 
shells were weighed accurately. Average weight of the powder for 20 capsules was 
calculated. A quantity of powder weigh equivalent to 10 mg of IPZ and 30 mg of DPD was 
weighed and transferred to a 25 ml volumetric flask and sufficient diluent was added to 
dissolve it. Then the solution was sonicated for 10 min. Final volume was adjusted with the 
same solvent and filtered through 0.45 µ membrane filter. 1 ml of the solution was pipetted 
out in a 100 ml dried and cleaned standard flask. This was then diluted with 30 ml of 
methanol. The volume was made up to 100 ml with same solvent. Resulting solution was 
then filtered through 0.45 µ membrane filter. The sample solution contains 4µg/ml of 
Ilaprazole and 12 µg/ml of Domperidone. 
Procedure:  
 Standard and sample solution were loaded on vial and injected into the chromatographic 
system with the help of auto injector separately. Injection has to be carried out by 5 replication of 
standard followed by sample. 
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Average weight of 20 capsules=  320.0 mg 
Weight taken = 316.18mg 
Label claim: 10 mg of Ilaprazole 
  30 mg of Domperidone 
Purity of Working Standard purity 
  Ilaprazole : 99.48% 
  Domperidone : 99.22% 
Weight taken for standard Solution  
Ilaprazole : 20.03 mg 
  Domperidone : 61.18 mg 
Figure 7.10: Chromatogram of Sample (Marketed Capsule) 
DRUG 
RETENTION 
TIME 
AREA 
AREA 
% 
THEORETICAL 
PLATES (USP) 
RESOLUTION 
(USP) 
ASYMMETRY 
DPD 0.598 149725 32.27 2249 0.00 1.70 
IPZ 2.072 306090 67.73 2589 16.75 1.85 
Total  451942 100.00    
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Calculation: 
The amount of Ilaprazole and Domperidone present in each capsule were calculated by using the 
following formula: 
 	

 
=
Sample Area
Standard Area
 X 
Standard  weight
Standard  Dilution
 X 
Sample Dilution
Sample weight
X
WS purity
100
 X Average weight 
%& =
Amount present
Label Claim
 X 100 
Table 7.3: Tabular column for the assay of Capsule sample 
Sl. 
No 
Drug 
Name 
Sample 
Area 
Standard 
Area 
Label claim 
(mg) 
Amount Present 
(mg) 
Assay 
% 
1 DPD 145831 149352 30 29.99 99.98 
2 IPZ 306090 308841 10 10.00 100.00 
 
Report:   The percentage purity of Domperidone and Ilaprazole were calculated in capsule dosage 
form and it was found to be 102.53 % and 100.00 % respectively. 
7.2.4 Linearity  
 The linearity of an analytical procedure is its ability (within a given range) to obtain test 
results which are directly proportional to the concentration (amount) of analyte in the sample. To 
demonstrate the linearity of analytes over the range 80% to 120% of target concentration five 
different concentration solutions of the DPD & IPZ (80%, 90%, 100%, 110%, and 120%) prepared 
and take injections in UPLC by the means of auto injector. 
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7.2.4.1 Procedure 
Stock Solution A (Ilaprazole) 
  Weighed accurately about 20 mg of Ilaprazole and transferred it to a 50 ml standard 
flask and sufficient methanol was added to dissolve it. Then the solution was sonicated for 
10 minutes and made the volume up to the mark with methanol. Final concentration was 
400μg/ml. 
Stock Solution B (Domperidone)  
  Weighed accurately about 60 mg of Domperidone and transferred it to a 50 ml 
standard flask and sufficient methanol was added to dissolve it. Then the solution was 
sonicated for 10 minutes and made the volume up to the mark with methanol. Final 
concentration was 1200 μg /ml. 
Actual weight taken, 
For stock solution A (Ilaprazole) =  20.03 mg 
For stock solution B (Domperidone) = 61.18 mg 
Preparation of 80% Solution: 
Dilute 0.8 ml of stock solution A and 0.8 ml of stock solution B in 100 ml volumetric flask and 
make up the volume up to the mark with same diluent. 
Preparation of 90% Solution: 
Dilute 0.9 ml of stock solution A and 0.9 ml of stock solution B in 100 ml volumetric flask and 
make up the volume up to the mark with same diluent. 
Preparation of 100% Solution: 
 
Dilute 1 ml of stock solution A and 1 ml of stock solution B in 100 ml volumetric flask and make 
up the volume up to the mark with same diluent. 
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Preparation of 110% Solution: 
 
Dilute 1.1 ml of stock solution A and 1.1 ml of stock solution B in 100 ml volumetric flask and 
make up the volume up to the mark with same diluent. 
Preparation of 120% Solution: 
 
Dilute 1.2ml of stock solution A and 1.2ml of stock solution B in 100 ml volumetric flask and make 
up the volume up to the mark with same diluent. 
Figure 7.11: Chromatogram of linearity solution (80%) 
DRUG 
RETENTION 
TIME 
AREA 
AREA 
% 
THEORETICAL 
PLATES (USP) 
RESOLUTION 
(USP) ASYMMETRY 
DPD 0.603 115657 32.29 2282 0.00 1.73 
IPZ 2.078 242560 67.71 2695 16.76 1.85 
Total  358217 100.00    
 
 
Figure 7.12: Chromatogram of linearity solution (90%) 
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Figure 7.13: Chromatogram of linearity solution (100%) 
 
 
Figure 7.14: Chromatogram of linearity solution (110%) 
 
 
Figure 7.15: Chromatogram of linearity solution (120%) 
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Table 7.4: Linearity results for Domperidone and Ilaprazole 
SL. NO LINEARITY LEVEL DOMPERIDONE (DPD) ILAPRAZOLE (IPZ) 
  
CONCENTRATION 
(µg/ml) AREA 
CONCENTRATION 
(µg/ml) AREA 
1 80% 9.79 115657 3.20 242560 
2 90% 11.01 131110 3.61 275505 
3 100% 12.24 145029 4.01 302861 
4 110% 13.46 159996 4.41 331534 
5 120% 14.68 174431 4.81 362008 
Correlation coefficient 0.999 0.999 
Slope 11973 73371 
 
 
 
 
Figure 7.16: Calibration graph of Domperidone 
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Figure 7.17: Calibration graph of Ilaprazole 
Acceptance criteria: Correlation coefficient ≥ 0.997 
Report: The relationship between the concentration and the peak response of Domperidone 
(DPD) and Ilaprazole (IPZ) were found linear in the specific range and regression 
coefficient for both Domperidone and Ilaprazole was found to be 0.999. 
 
7.2.5 Accuracy  
Accuracy of the method was determined by recovery experiments. Recovery study can be carried 
out by spiking study or swab study (usually for cleaning validation). In my experiment I performed 
spiking method.  To the formulation, the working standards of the drug were added at the level of 
100%, 110%, 120% and 130%. Prepare each level in triplicate injection and the average is taken to 
calculate the percentage relative standard deviation was calculated. 
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7.2.5.1 Procedure 
Preparation of Spike Stock Solution 
Weigh accurately 30 mg of Domperidone WS and 10 mg of Ilaprazole WS in a 100 ml of 
standard flask, dissolve in 25 ml diluent and solution was sonicated for 10 min. Make up the 
volume with the same diluent and filtered through 0.45 µ membrane filter. 
Weight taken, 
 Ilaprazole =  10.01 mg 
Domperidone = 30.06 mg 
7.2.5.2 Preparation of 100% solution 
 Weighed accurately 320 mg of sample and transferred into a 25 ml volumetric flask 
and sufficient diluent was added to dissolve it. Then the solution was sonicated for 10 min. 
Volume was adjusted with the same solvent and filtered through 0.45 µ membrane filter. 1 
ml of above solution was diluted with 30 ml of diluent in a 100 ml volumetric flask and final 
volume was adjusted with the same solvent 
7.2.5.3 Preparation of 110% solution 
 Weighed accurately 320 mg of sample and transferred into a 25 ml volumetric flask 
and add sufficient diluent to dissolve it.Then the solution was sonicated for 10 min. Volume 
was adjusted with the same diluent and filtered through 0.45 µ membrane filter. To 1 ml of 
the above solution add 10 ml of standard spike solution and sufficient diluent was added to 
make up the volume. 
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7.2.5.4 Preparation of 120% solution 
 Weighed accurately 320 mg of sample and transferred into a 25 ml volumetric flask 
and add sufficient diluent to dissolve it. Then the solution was sonicated for 10 min. Volume 
was adjusted with the same diluent and filtered through 0.45 µ membrane filter. To 1 ml of 
the above solution add 20 ml of standard spike solution and sufficient diluent was added to 
make up the volume. 
7.2.5.5 Preparation of 130% solution: 
 Weighed accurately 320 mg of sample and transferred into a 25 ml volumetric flask 
and add sufficient diluent to dissolve it. Then the solution was sonicated for 10 min. Volume 
was adjusted with the same diluent and filtered through 0.45 µ membrane filter. To 1 ml of 
the above solution add 30 ml of standard spike solution and sufficient diluent was added to 
make up the volume. 
Table 7.5: Tabular Column for Recovery Solution 
ACCURACY 
SOLUTION 
(%) 
WEIGHT 
OF 
SAMPLE 
(mg) 
THEORETICALLY 
PRE-EXISTING DPD 
( mg/capsule) 
THEORETICALLY 
PRE-EXISTING IPZ 
(mg/capsule) 
AMOUNT SPIKED 
(mg) 
VOLUME 
(ml) 
DPD IPZ 
100 320.01 29.99 10.00 -- -- -- 
110 320.03 29.99 10.00 10 0.122 0.040 
120 320.03 29.99 10.00 20 0.245 0.080 
130 320.02 29.99 10.00 30 0.367 0.120 
% Recovery
=
Actual calculated amount in recovery sample
Amount spiked in to the recovery sample + Calculated theoritical pre existing amount
 X 100 
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Figure 7.18: Chromatogram of accuracy 100% injection 01 
DRUG 
RETENTION 
TIME 
AREA 
AREA 
% 
THEORETICAL 
PLATES (USP) 
RESOLUTION 
(USP) 
ASYMMETRY 
DPD 0.602 147483 32.47 2269 0.00 1.76 
IPZ 2.070 306783 67.53 2629 16.76 1.82 
Total  454266 100.00    
 
Figure 7.19: Chromatogram of accuracy 100% injection 02 
Figure 7.20: Chromatogram of accuracy 100% injection 03 
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Figure 7.21: Chromatogram of accuracy 110% injection 01 
 
Figure 7.22: Chromatogram of accuracy 110% injection 02 
 
Figure 7.23: Chromatogram of accuracy 110% injection 03 
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Figure 7.24: Chromatogram of accuracy 120% injection 01 
 
Figure 7.25: Chromatogram of accuracy 120% injection 02 
 
Figure 7.26: Chromatogram of accuracy 120% injection 03 
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Figure 7.27: Chromatogram of accuracy 130% injection 01 
 
Figure 7.28: Chromatogram of accuracy 130% injection 02 
 
Figure 7.29: Chromatogram of accuracy 130% injection 03 
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Table 7.6: Accuracy results of Domperidone 
% 
LEVEL 
AREA 
AMOUNT 
FOUND (mg) 
% 
RECOVERY 
% MEAN 
RECOVERY 
% RSD 
100% 
147483 29.97 99.94 
99.92 0.02 147461 29.97 99.92 
147437 29.96 99.90 
110% 
162086 32.94 99.82 
99.82 0.00 162090 32.94 99.82 
162083 32.94 99.82 
120% 
176530 35.87 99.64 
99.59 0.12 176200 35.80 99.45 
176601 35.89 99.68 
130% 
191447 38.90 99.73 
99.69 0.05 186250 38.86 99.63 
188412 38.90 99.71 
Average 99.75 0.05 
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Table 7.7: Accuracy results of Ilaprazole 
% 
LEVEL 
AREA 
AMOUNT 
FOUND (mg) 
% 
RECOVERY 
% MEAN 
RECOVERY 
% RSD 
100% 
306783 9.90 99.02 
99.04 0.02 306887 9.91 99.06 
306890 9.91 99.06 
110% 
338770 10.93 99.39 
99.29 0.12 338541 10.93 99.32 
338005 10.91 99.17 
120% 
369649 11.93 99.41 
99.34 0.07 369431 11.92 99.35 
369117 11.91 99.26 
130% 
399302 12.89 99.12 
99.14 0.08 399165 12.88 99.08 
399771 12.90 99.23 
Average 99.20 0.07 
 
Acceptance Criteria 
The percentage recovery calculated should be between 98 to 102%. 
% RSD of each level should be NMT 2.0. 
Report 
The average percentage recovery for DPD and IPZ was found to be 99.75% and 99.20% 
respectively. 
The average percentage RSD for DPD and IPZ was found to be 0.05% and 0.07% respectively. 
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7.2.6 Precision  
Demonstrate the method precision by preparing six samples as per the test method of a 
single batch representing the 100% of test concentration. Determine the assay of these samples and 
evaluate the precision of the method by the % RSD of the assay results. 
Figure 7.30: Chromatogram of Precision solution – l 
DRUG 
RETENTION 
TIME 
AREA 
AREA 
% 
THEORETICAL 
PLATES (USP) 
RESOLUTION 
(USP) 
ASYMMETRY 
DPD 0.600 147059 32.46 2295 0.00 1.67 
IPZ 2.073 306022 67.54 2614 16.80 1.80 
Total  453081 100.00    
 
Figure 7.31: Chromatogram of Precision solution – ll 
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Figure 7.32: Chromatogram of Precision solution – lll 
 
Figure 7.33: Chromatogram of Precision solution – lV 
 
Figure 7.34: Chromatogram of Precision solution – V 
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Figure 7.35: Chromatogram of Precision solution – Vl 
Table 7.8: Method precision results for Domperidone & Ilaprazole 
INJECTION 
NO. 
SAMPLE 
WEIGHT 
(mg) 
DOMPERIDONE (DPD) ILAPRAZOLE (IPZ) 
AREA %ASSAY AREA %ASSAY 
1 316.25 147059 100.78 306022 99.97 
2 316.37 147045 100.74 306022 99.94 
3 316.18 147048 100.80 306076 100.00 
4 316.19 147087 100.80 306019 99.99 
5 316.17 147068 100.80 306024 100.00 
6 316.20 147026 100.79 306093 99.99 
Average 147055.50 100.79 306042.7 99.98 
Standard Deviation 20.96 0.02 32.89 0.02 
% RSD 0.01 0.02 0.01 0.02 
Acceptance criteria: Percentage RSD ≤ 2 
Report:  
• The above precision study was assessed by repeatability tests.  
• The % RSD for the area and assay of DPD found to be 0.01 and 0.02 respectively. 
• The % RSD for the area and assay of IPZ was found to be 0.01 and 0.2 respectively. 
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7.2.7 Limit of detection (LOD) & Limit of Quantitation (LOQ) 
The LOD and LOQ of DPD and IPZ shall be estimated from the standard deviation 
of the response and the slope of the calibration curve by using the following formula 
     LOD =  2.2×5
6
  LOQ =  78×5
6
  
 
Where   σ   = the standard deviation of the response 
  S   = the slope of the calibration curve 
Table 7.9: LOD & LOQ Determination 
NAME SLOPE 
STANDARD DEVIATION 
OF RESPONSE 
LOD  
(µg/ml) 
LOQ  
(µg/ml) 
Domperidone (DPD) 11973 20.96 0.006 0.018 
Ilaprazole (IPZ) 73371 32.89 0.001 0.004 
 
Report:  
• The LOD and LOQ of DPD for this method were found to be 0.006 µg/ml and 0.018µg/ml 
respectively. 
• The LOD and LOQ ofIPZ for this method were found to be 0.001 µg/ml and 0.004 µg/ml 
respectively. 
7.2.8 Robustness 
Robustness of the method was checked by small deliberate changes in the method 
parameters such as wavelength (±2nm) and flow rate (±0.025ml) which shall not much affect in 
theoretical plates and peak asymmetry. 
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Figure 7.36: Chromatogram of robustness at wavelength 286 nm  
DRUG 
RETENTION 
TIME 
AREA 
AREA 
% 
THEORETICAL 
PLATES (USP) 
RESOLUTION 
(USP) ASYMMETRY 
DPD 0.602 146223 31.82 2240 0.00 1.71 
IPZ 2.082 313376 68.18 2570 16.80 1.85 
Total  459599 100.00    
 
Figure 7.37: Chromatogram of robustness at wavelength 290 nm  
DRUG 
RETENTION 
TIME 
AREA 
AREA 
% 
THEORETICAL 
PLATES (USP) 
RESOLUTION 
(USP) 
ASYMMETRY 
DPD 0.602 144409 31.37 2276 0.00 1.58 
IPZ 2.062 315859 68.63 2536 16.81 1.84 
Total  460268 100.00    
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Figure 7.38: Chromatogram of robustness (flow rate at 0.375 ml /min) 
DRUG 
RETENTION 
TIME 
AREA 
AREA 
% 
THEORETICAL 
PLATES (USP) 
RESOLUTION 
(USP) 
ASYMMETRY 
DPD 0.657 146213 32.07 2228 0.00 1.59 
IPZ 1.985 309729 67.93 2265 16.75 1.80 
Total  455942 100.00    
 
Figure 7.39: Chromatogram of robustness (flow rate at 0.425 ml /min) 
DRUG 
RETENTION 
TIME 
AREA 
AREA 
% 
THEORETICAL 
PLATES (USP) 
RESOLUTION 
(USP) ASYMMETRY 
DPD 0.552 143529 32.13 2254 0.00 1.64 
IPZ 2.097 303132 67.87 2598 16.77 1.94 
Total  446661 100.00    
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Table 7.10: Robustness observation of Domperidone 
SL. 
NO 
PARAMETER CONDITION 
RETENTION 
TIME 
(min) 
AREA 
THEORETICAL 
PLATES (USP) 
ASYMMETRY 
1 
Wavelength 
variation 
286 nm 0.602 146223 2240 1.71 
288 nm 0.598 145852 2249 1.7 
290 nm 0.602 144409 2276 1.58 
% RSD -- 0.66 -- -- 
2 
 
Flow Rate 
 
0.375ml 
/min 0.657 146213 2228 1.59 
0.400ml 
/min 0.598 145852 2249 1.7 
0.425ml 
/min 0.552 143529 2254 1.64 
% RSD -- 1.00 -- -- 
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Table 7.11: Robustness observation of Ilaprazole 
SL. 
NO 
PARAMETER CONDITION 
RETENTION 
TIME 
(min) 
AREA 
THEORETICAL 
PLATES (USP) 
ASYMMETRY 
1 
Wavelength 
variation 
286 nm 2.082 313376 2570 1.85 
288 nm 2.072 306090 2589 1.85 
290 nm 2.062 315859 2536 1.84 
% RSD -- 1.63 -- -- 
2 
 
Flow Rate 
 
0.375ml 
/min 1.985 309729 2265 1.8 
0.400ml 
/min 2.072 306090 2589 1.85 
0.425ml 
/min 2.097 303132 2598 1.94 
% RSD -- 1.08 -- -- 
Acceptance Criteria:   % RSD ≤ 2 
Theoretical plates (USP) ≥ 2000 
     Asymmetry ≤ 2 
Report:  
The robustness was tested by changing the wavelength and flow rate in the chromatographic 
parameters. It has been found that change in flow rate leads to little change in retention time.  
The percentage RSD for wavelength variation of Domperidone and Ilaprazole was found to 
0.66% and 1.63% respectively. 
The percentage RSD for flow rate variation of Domperidone and Ilaprazole was found to 
1.00% and 1.08% respectively. 
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8. RESULTS AND DISCUSSION 
8.1 RESULTS 
The analytical method for the Domperidone and Ilaprazole by UPLC was established then 
optimized and applied on pharmaceutical dosage forms.  
Various trials were performed in order to optimize the following analytical parameter like 
choice of column, mobile phase composition, flow rate and injection volume and the results are 
shown in table 8.1. 
Table 8.1: Tabular column for analytical parameters 
Column C18(50 X 2.1 mm, 1.9 µm); Make Thermo 
Mobile phase composition 
Water : Methanol : ACN : Acetic Acid 
(30:20:50:0.3) finally adjust the pH to 5.0 with 
Triethylamine 
Diluent Methanol 
Flow rate 0.4 ml/min 
Column temperature Ambient 
Injection volume 10 µl 
Pump mode Isocratic 
PDA detection 288 nm 
As per above mentioned analytical method the assay of Domperidone and Ilaprazole for 
marketed formulation (Capsule dosage form) was carried out and the content and percentage purity 
are mentioned in table 8.2. 
Table 8.2: Results of assay of DPD&IPZ in capsule dosage form 
SL. NO DRUG NAME 
LABEL 
CLAIM 
CONTENT 
PRESENT 
PERCENTAGE 
PURITY 
1 Domperidone 30 mg 29.99 mg 99.98% 
2 Ilaprazole 10 mg 10.00 mg 100.00% 
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Table 8.3:Results of Validation Parameters 
Validation 
Parameter 
Acceptance Criteria 
Observation 
Remarks 
DPD IPZ 
Specificity 
The peaks of diluent and excipients 
should not interfere with the main peak 
and peak of standard and sample should 
be identical with near retention time. 
Complies Complies - 
System 
Suitability 
Asymmetry NMT 2.0 1.69 1.82 
Complies Theoretical plates NMT 2000 2264.80 2620 
%RSD of area NMT 2.0 0.381 0.388 
Linearity Correlation Coefficient NLT 0.997 0.999 0.999 Complies 
Accuracy 
The % recovery at each spike level shall 
be NLT 98.0% and NMT 102.0% of the 
added amount. 
99.59-99.92% 99.04-99.34% 
Complies 
% RSD of each level should be NMT 
2.0 
Average % 
RSD = 0.05 
Average % 
RSD = 0.07 
Precision 
The % RSD of area for the six 
determinations shall be NMT 2.0. 
0.01 0.01 
Complies 
 The % RSD of assay for the six 
determinations shall be NMT 2.0. 
0.02 0.02 
LOD 
(µg/ml) 
Not specified 0.006 0.001 Suitable 
LOQ 
(µg/ml) 
Not specified 0.018 0.004 Suitable 
Robustness 
Theoretical plates (USP) ≥ 2000 Complies Complies 
- 
Asymmetry ≤ 2 Complies Complies 
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8.2 DISCUSSION 
A simple and rapid RP-UPLC method was developed for the simultaneous estimation of 
Domperidone and Ilaprazole in pharmaceutical dosage form. For the analysis, the mobile phase 
selected consists of mixture of Water : Methanol : ACN : Acetic Acid (30:20:50:0.3)and finally 
pH was adjusted to 5.0 with Triethylamine. Column suitable for this method was found C18 (50 X 
2.1 mm, 1.9 µm); Make Thermo. 
From the spectral characteristic, the detection was carried out by using PDA detector at 288 
nm. The retention time is for DPD&IPZ was found 0.598 min&2.072 min respectively. The 
asymmetry factor was found to be 1.70 and 1.85, which indicates symmetrical nature of the peak. 
Resolution (USP) between two peaks was 16.81 which will satisfy the acceptance criteria. 
The specificity was performed with respect blank and identification and the chromatogram 
showed was identical with near retention time with standard. 
The System suitability parameter such as retention time, number of theoretical plates, and 
asymmetry factor, % RSD of area were recorded and found to be within limits mentioned in table 
7.1 & 7.2. 
With the optimized conditions, linearity range was fixed as (80-120) % i.e. (80-120) µg/ml 
of DPD and (8-12) µg/ml of IPZ. Linearity range was evaluated by the visual inspection of plot of 
peak area as a function of analyte concentration and the corresponding calibration graphs were 
shown in figure 6.15 & 6.16and results are shown in table 6.3. From the linearity studies, the 
specified concentration range was determined. It was observed that Domperidone and Ilaprazole 
were linear in the range of (9.79-14.68) µg/ml and (3.20-4.81) µg/ml respectively for the target 
concentrations. The regression equation of Domperidone and Ilaprazole for concentration over its 
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peak area ratio was found to be y=11973x-1259(R² = 0.999) and y=73371x+8822(R² = 0.999) 
where y is the peak area ratio and x is the concentration of DPD&IPZ in µg/ml.  
The validation of proposed method was verified by recovery (spiking) studies. The 
percentage recovery range was found between 99.59-99.92% for DPD and 99.04-99.34% for IPZ. 
This is a good index of accuracy, specificity and repeatability of the method. The results were 
tabulated in table 7.6 & 7.7. All parameters including flow rate, temperature, detection, wavelength 
and sensitivity are maintained constant throughout the procedure. 
The validation of the proposed method was verified by method precision where repeatability 
study was performed by preparing six samples as per the test method of a single batch representing 
the 100% of test concentration. The %RSD of assay and area for method precision were calculated 
and the data was tabulated and shown in table 7.8.  
LOD and LOQ were calculated from the linearity parameter data. The results were tabulated 
and shown in table 7.9. 
Robustness studies were made by varying wavelength (±2 nm) and flow rate (±0.025 
ml/min) and the results were mentioned in table 7.10 & 7.11. 
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8. SUMMARY & CONCLUSION 
8.1 SUMMARY 
From the literature review it was found that no UPLC method was carried out for the 
simultaneous determination of Domperidone and Ilaprazole in capsule dosage form. Various trials 
were conducted by varying the wavelength, column, mobile phase, and flow rate and injection 
volume and the parameters for UPLC method for the determination of DPD and IPZcapsule dosage 
form were optimized. 
The scope of the present work is to expand the optimization of the chromatographic 
conditions and to develop new RP-UPLC method. A series of mobile phases were tried and among 
the various mobile phase comprising of mixture of Water : Methanol : ACN : Acetic Acid 
(30:20:50:0.3) (pH 5.0, adjusted with Triethylamine) was chosen as an ideal mobile phase, since 
it a good resolution and peak shapes with perfect optimization. The detection was carried out at 288 
nm by using PDA detector. The flow rate was optimized at 0.4 ml/min. 
The Specificity of DPD and IPZ were shown in Chromatograms. There was no interference 
in this method and good separation between all peaks. It means no impurity was interfered and also 
reveals that commonly used excipients and additives present in the capsule dosage form were not 
interfering in the proposed methods. It was also found that the retention time of sample DPD and 
IPZ were identical corresponding to standard DPD and IPZ. 
The system suitability was found within the limits. The % RSD for DPD and IPZ were 
found 0.381% and 0.388% respectively. Theoretical plates, resolution and Asymmetry factor also 
found suitable.   
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The linearity obtained from calibration graph shows that DPD and IPZ were linear in the 
range of (9.79-14.68) µg/ml and (3.20-4.81) µg/ml respectively. Correlation coefficient in the range 
of (9.79-14.68)µg/ml for DPD and (3.20-4.81) µg/ml for IPZ were calculated and found 0.999 and 
0.999 respectively. 
In assay of marketed formulation the percentage purity of DPD and IPZ were found 102.53 
% and 100.00% respectively which indicate that the method can be used to determine the 
percentage purity of Domperidone and Ilaprazole in capsule dosage form. 
Accuracy study was carried out by spiking method where calculated known amount of standard 
were added for different Percentage levels (100% - 130%). The average percentage recovery for 
DPD and IPZ was found to be 99.75% and 99.20% respectively. The average percentage RSD for 
DPD and IPZ was found to be 0.05% and 0.07% respectively. 
The limits of % recovery studies are in the range of 98-102% and the results found that 
recovery values of pure drugs from the solution were as well, which indicates that the method is 
accurate. 
Method Precision was assessed by repeatability tests (6 determinations at the level of 100% 
concentration). The % RSD for the area and assay of DPD found to be 0.01 and 0.02 respectively. 
The % RSD for the area and assay of IPZ was found to be 0.01 and 0.2 respectively. 
Hence method is precise for DPD and IPZ. The complete data regarding the precision was shown in 
table11. 
Based on standard deviation response (standard deviation of y intercept obtained from the 
calibration curve) and slope, the Limit of detection (LOD) and Limit of Quantitation (LOQ) were 
calculated for DPD and IPZ. The Limit of detection (LOD) of DPD and IPZ were found 0.006µg/ml 
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and 0.001µg/ml respectively. And the Limit of Quantitation (LOQ) of DPD and IPZ were found 
0.018µg/ml and 0.004µg/ml respectively. 
Robustness of the method was checked by small deliberate changes in the method 
parameters such as wavelength (±2nm) and flow rate (±0.2ml) but these changes did not affect the 
chromatographic parameter and the method results which indicate that the method is robust. 
 
8.2 CONCLUSION 
Thus the proposed method was found to be simple, accurate, precise and rapid for 
simultaneous estimation of Domperidone and Ilaprazole in pharmaceutical capsule dosage form and 
could be used for routine analysis. All the parameters meet the criteria of ICH guidelines for 
method validation and found to be simple, sensitive, accurate and precise. It can therefore be 
concluded that the reported method is more economical and can find practical application for 
simultaneous analysis of the Domperidone (DPD) and Ilaprazole (IPZ) in their combined dosage 
forms both in research and quality control laboratories 
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